```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 10   Time limit for inactive STN sessions doubles to 40
                   minutes
 NEWS  3  AUG 18   COMPENDEX indexing changed for the Corporate Source
                   (CS) field
 NEWS  4  AUG 24   ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS  5  AUG 24   CA/CAplus enhanced with legal status information for
                   U.S. patents
 NEWS  6  SEP 09   50 Millionth Unique Chemical Substance Recorded in
                   CAS REGISTRY
 NEWS  7  SEP 11   WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                   thesaurus
 NEWS  8  OCT 21   Derwent World Patents Index Coverage of Indian and
                   Taiwanese Content Expanded
 NEWS  9  OCT 21   Derwent World Patents Index enhanced with human
                   translated claims for Chinese Applications and
                   Utility Models
 NEWS 10  OCT 27   Free display of legal status information in CA/CAplus,
                   USPATFULL, and USPAT2 in the month of November.

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:16:38 ON 16 NOV 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 19:16:44 ON 16 NOV 2009
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2009 HIGHEST RN 1192409-16-7
DICTIONARY FILE UPDATES: 15 NOV 2009 HIGHEST RN 1192409-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10566842narrow.str





chain nodes :
22 23 24 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20
chain bonds :
1-23 4-22 9-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
 15-16 16-17 16-18 17-20 18-19 19-20
exact/norm bonds :
1-23 4-22 9-24 12-13 12-17 13-14 14-15 15-16 16-17 16-18 17-20 18-19
19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 1 : 12 :

G1:O,S

G2:H,Ak

G3:CH,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
22:CLASS 23:CLASS 24:CLASS 28:CLASS 29:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR





G1 O,S

G2 H,Ak

G3 CH,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 19:17:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 29234 TO ITERATE

100.0% PROCESSED 29234 ITERATIONS 608 ANSWERS
SEARCH TIME: 00.00.03

L2 608 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 19:17:15 ON 16 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Nov 2009 VOL 151 ISS 21
FILE LAST UPDATED: 15 Nov 2009 (20091115/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free! Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.

```
=> s l2 and (pry<2004 or py<2004)
           154 L2
       4288130 PRY<2004
      24042947 PY<2004
L3           31 L2 AND (PRY<2004 OR PY<2004)

=> d 1-31 ibib abs hitstr
```

L3 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:588947 CAPLUS
DOCUMENT NUMBER: 143:103197
TITLE: Maleate salts of a quinazoline derivative used as an antiangiogenic agent
INVENTOR(S): McCabe, James
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061488	A1	20050707	WO 2004-GB5359	20041218 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004303590	A1	20050707	AU 2004-303590	20041218	<--
AU 2004303590	B2	20090730			
CA 2548662	A1	20050707	CA 2004-2548662	20041218	<--
EP 1699782	A1	20060913	EP 2004-806159	20041218	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1898232	A	20070117	CN 2004-80038665	20041218	<--
BR 2004017958	A	20070327	BR 2004-17958	20041218	<--
JP 2007517008	T	20070628	JP 2006-546311	20041218	<--
US 20070129387	A1	20070607	US 2006-581279	20060601	<--
NO 2006002703	A	20060720	NO 2006-2703	20060612	<--
MX 2006007191	A	20060823	MX 2006-7191	20060622	<--
ZA 2006005225	A	20070530	ZA 2006-5225	20060623	<--
IN 2006MN00832	A	20070413	IN 2006-MN832	20060714	<--
KR 2006127899	A	20061213	KR 2006-714753	20060721	<--
PRIORITY APPLN. INFO.:			GB 2003-30002 A	20031224	<--
			WO 2004-GB5359 W	20041218	

AB The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compns. containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability. For example, AZD2171 maleate form A was prepared by mixing AZD2171 and maleic acid in isopropanol.

IT 857036-77-2P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal forms of AZD2171 maleate used as antiangiogenic agents)

RN 857036-77-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 288383-20-0, AZD2171
RL: RCT (Reactant); RACT (Reactant or reagent)
(crystal forms of AZD2171 maleate used as antiangiogenic agents)
RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:570826 CAPLUS
DOCUMENT NUMBER: 143:103193
TITLE: Optical imaging contrast agents for imaging lung cancer
INVENTOR(S): Klaveness, Jo; Johannesen, Edvin; Tolleshaug, Helge
PATENT ASSIGNEE(S): Amersham Health AS, Norway
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058370	A1	20050630	WO 2004-NO392	20041217 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070212305	A1	20070913	US 2006-582893	20061207 <--
PRIORITY APPLN. INFO.:			NO 2003-5681 A	20031218 <--
			WO 2004-NO392 W	20041217

AB The invention provides contrast agents for optical imaging of lung cancer in patients. The contrast agents may be used in diagnosis of lung cancer, for follow up of progress in disease development, for follow up of treatment of lung cancer and for surgical guidance. Further, the invention provides methods for optical imaging of lung cancer in patients.

IT 855309-69-2P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(targeted imaging agents for lung cancer diagnosis)

RN 855309-69-2 CAPLUS

CN 3H-Indolium, 2-[7-[1-[6-[2-[3-[[4-[(3-bromophenyl)amino]-6-quinazolinyl]amino]-3-oxopropyl]hydrazinyl]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

PAGE 1-A





REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:567137 CAPLUS
DOCUMENT NUMBER: 143:83434
TITLE: Optical imaging contrast agents for imaging of prostate cancer
INVENTOR(S): Klaveness, Jo; Johannesen, Edvin; Tolleshaug, Helge
PATENT ASSIGNEE(S): Amersham Health AS, Norway
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005058372	A1	20050630	WO 2004-NO394		20041217 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20080044350	A1	20080221	US 2007-582842		20070502 <--
PRIORITY APPLN. INFO.:			NO 2003-5683	A	20031218 <--
			WO 2004-NO394	W	20041217

AB The invention provides contrast agents for optical imaging of prostate cancer in patients. The contrast agents may be used in diagnosis of prostate cancer, for follow up of progress in disease development, for follow up of treatment of prostate cancer and for surgical guidance. Further, the invention provides methods for optical imaging of prostate cancer in patients.

IT 855309-69-2P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(targeted contrast agents for imaging of prostate cancer)
RN 855309-69-2 CAPLUS
CN 3H-Indolium, 2-[7-[1-[6-[2-[3-[[4-[(3-bromophenyl)amino]-6-quinazolinyl]amino]-3-oxopropyl]hydrazinyl]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:564588 CAPLUS
DOCUMENT NUMBER: 143:103192
TITLE: Optical imaging contrast agents
INVENTOR(S): Klaveness, Jo; Johannesen, Edvin; Tolleshaug, Helge
PATENT ASSIGNEE(S): Amersham Health AS, Norway
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058371	A1	20050630	WO 2004-NO393	20041217 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1694365	A1	20060830	EP 2004-808887	20041217 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20070258904	A1	20071108	US 2007-582679	20070517 <--

PRIORITY APPLN. INFO.: NO 2003-5682 A 20031218 <--
WO 2004-NO393 W 20041217

AB The invention provides contrast agents for optical imaging of esophageal cancer and Barrett's esophagus in patients. The contrast agents may be used in diagnosis of esophageal cancer and Barrett's esophagus, for follow up of progress in disease development, for follow up of treatment of esophageal cancer and Barrett's esophagus and for surgical guidance. Further, the invention provides methods for optical imaging of esophageal cancer and Barrett's esophagus in patients.

IT 855309-69-2P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(optical imaging contrast agents targeted to esophageal cancer and Barrett's esophagus)

RN 855309-69-2 CAPLUS

CN 3H-Indolium, 2-[7-[1-[6-[2-[3-[[4-[(3-bromophenyl)amino]-6-quinazolinyl]amino]-3-oxopropyl]hydrazinyl]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-1-ethyl-3,3-dimethyl-5-sulfo-, inner salt (CA INDEX NAME)





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:141059 CAPLUS
DOCUMENT NUMBER: 142:240453
TITLE: Preparation of quinazolines as inhibitors of VEGF receptor tyrosine kinases
INVENTOR(S): Hennequin, Laurent Francois Andre
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014582	A1	20050217	WO 2004-GB3376	20040805 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004263360	A1	20050217	AU 2004-263360	20040805 <--
CA 2534811	A1	20050217	CA 2004-2534811	20040805 <--
EP 1658280	A1	20060524	EP 2004-743664	20040805 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004013284	A	20061010	BR 2004-13284	20040805 <--
CN 1863794	A	20061115	CN 2004-80029079	20040805 <--

JP 2007501210	T	20070125	JP 2006-522400		20040805	<--
US 20080058342	A1	20080306	US 2006-566842		20060202	<--
MX 2006001395	A	20060519	MX 2006-1395		20060203	<--
ZA 2006001025	A	20070530	ZA 2006-1025		20060203	<--
KR 2006058705	A	20060530	KR 2006-702540		20060206	<--
NO 2006000650	A	20060424	NO 2006-650		20060209	<--
PRIORITY APPLN. INFO.:			GB 2003-18422	A	20030806	<--
			WO 2004-GB3376	W	20040805	

OTHER SOURCE(S): CASREACT 142:240453; MARPAT 142:240453

GI



I



II

AB Title compds. I [wherein A = 8, 9, 10, 12, or 13-membered bicyclic or tricyclic (un)saturated (non)aromatic; Z = O, NH, S; n = 0-5; m = 0-3; R2 = each independently H, OH, halo, CN, NO2, CF3, alkyl, alkoxy, etc.; R1 = each independently H, Me, F; and their salts] were prepared for the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm blooded animals. Thus, II was prepared by O-alkylation of 2,3-dimethyl-5-hydroxyindole with 4-chloro-7-(2-chloroethoxy)-6-methoxyquinazoline (preparation given), and amination of the chloride with 1-(acetylmethyl)piperazine. I inhibited gene flt-1 and KDR VEGF receptor tyrosine kinase, FGF, and EGFR receptor with IC50 values < 5 μM in an in vivo test. I inhibited the growth factor--stimulated proliferation of HUVEC cells with IC50 values in the range of 0.001 - 5 μM. II displayed an IC50 = 10.1 μM in an hERG-encoded potassium channel inhibition test. I and their pharmaceutically acceptable salts are useful for treating disease states associated with angiogenesis and/or increased vascular permeability, for e.g. cancer and rheumatoid arthritis.

IT 844659-27-4P, 7-[[1-(Acetylmethyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 844659-33-2P, 7-[[1-(Acetylmethyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]quinazoline 844659-36-5P,

7-[[1-(Acetylmethyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844659-40-1P, 6-Methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[[1-[(pyrrolidin-1-yl)acetyl]piperidin-4-yl]methoxy]quinazoline 844659-44-5P, 6-Methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[[1-[(pyrrolidin-1-yl)acetyl]piperidin-4-yl]methoxy]quinazoline 844659-48-9P, 6-Methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[(pyrrolidin-1-yl)acetyl]piperidin-4-yl]methoxy]quinazoline 844659-53-6P, 6-Methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(tetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]quinazoline 844659-60-5P, 6-Methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(tetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]quinazoline 844659-64-9P, 4-[(2,3-Dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]quinazoline 844659-68-3P, 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]quinazoline 844659-71-8P, 7-[2-[4-(Acetylmethyl)piperazin-1-yl]ethoxy]-4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 844659-74-1P, 7-[2-[4-(Acetylmethyl)piperazin-1-yl]ethoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 844659-78-5P, 7-[2-[4-(Acetylmethyl)piperazin-1-yl]ethoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844659-83-2P, 7-[2-[4-(Acetylmethyl)piperazin-1-yl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 844659-91-2P, 7-[[1-(Acetylmethyl)piperidin-4-yl]oxy]-6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]quinazoline 844659-99-0P, 7-[[1-(Acetylmethyl)piperidin-4-yl]oxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844660-05-5P, 7-[[1-(Acetylmethyl)piperidin-4-yl]oxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(angiogenesis inhibitor; preparation of quinazolines as inhibitors of VEGF receptor tyrosine kinases and their use for treating angiogenesis and/or increased vascular permeability)

RN 844659-27-4 CAPLUS
CN 2-Propanone, 1-[4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-33-2 CAPLUS
CN 2-Propanone, 1-[4-[[[6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-36-5 CAPLUS
CN 2-Propanone, 1-[4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-40-1 CAPLUS
CN Ethanone, 1-[4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 844659-44-5 CAPLUS
CN Ethanone, 1-[4-[[[6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 844659-48-9 CAPLUS
CN Ethanone, 1-[4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 844659-53-6 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]- (CA INDEX NAME)



RN 844659-60-5 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]- (CA INDEX NAME)



RN 844659-64-9 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]- (CA INDEX NAME)



RN 844659-68-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]- (CA INDEX NAME)



RN 844659-71-8 CAPLUS
CN 2-Propanone, 1-[4-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 844659-74-1 CAPLUS
CN 2-Propanone, 1-[4-[2-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 844659-78-5 CAPLUS
CN 2-Propanone, 1-[4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 844659-83-2 CAPLUS
CN 2-Propanone, 1-[4-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 844659-91-2 CAPLUS
CN 2-Propanone, 1-[4-[[6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-quinazolinyl]oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-99-0 CAPLUS

CN 2-Propanone, 1-[4-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 844660-05-5 CAPLUS
CN 2-Propanone, 1-[4-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-1-piperidinyl]- (CA INDEX NAME)



IT 288382-74-1P, 6-Methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(piperidin-4-yl)methoxy]quinazoline 288386-84-5P, 7-[[1-(tert-Butoxycarbonyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 288386-90-3P, 6-Methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[(piperidin-4-yl)methoxy]quinazoline 574746-13-7P, 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(piperazin-1-yl)ethoxy]quinazoline 844659-31-0P, 6-Methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[(piperidin-4-yl)methoxy]quinazoline 844659-38-7P, 7-[[1-(Chloroacetyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 844659-42-3P, 7-[[1-(Chloroacetyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]quinazoline 844659-46-7P, 7-[[1-(Chloroacetyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844659-50-3P, 7-(2-Chloroethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844659-58-1P, 7-(2-Chloroethoxy)-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 844659-62-7P, 7-(2-Chloroethoxy)-4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 844659-66-1P, 7-(2-Chloroethoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 844659-76-3P, 6-Methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(piperazin-1-yl)ethoxy]quinazoline 844659-80-9P, 7-[2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]ethoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844659-85-4P, 7-[2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 844659-87-6P, 7-[2-[4-(Chloroacetyl)piperazin-1-yl]ethoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844659-88-7P,

6-Methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-[4-[(pyrrolidin-1-yl)acetyl]piperazin-1-yl]ethoxy]quinazoline 844659-90-1P,
6-Methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[(piperidin-4-yl)oxy]quinazoline 844659-95-6P,
7-[[1-(tert-Butoxycarbonyl)piperidin-4-yl]oxy]-6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]quinazoline 844659-97-8P,
6-Methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(piperidin-4-yl)oxy]quinazoline 844660-01-1P,
7-[[1-(tert-Butoxycarbonyl)piperidin-4-yl]oxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline 844660-03-3P,
4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(piperidin-4-yl)oxy]quinazoline 844660-07-7P,
7-[[1-(tert-Butoxycarbonyl)piperidin-4-yl]oxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines as inhibitors of VEGF receptor tyrosine kinases and their use for treating angiogenesis and/or increased vascular permeability)

RN 288382-74-1 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 288386-84-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288386-90-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 574746-13-7 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 844659-31-0 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 844659-38-7 CAPLUS
CN Ethanone, 2-chloro-1-[4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-42-3 CAPLUS

CN Ethanone, 2-chloro-1-[4-[[[6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-46-7 CAPLUS
CN Ethanone, 2-chloro-1-[4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 844659-50-3 CAPLUS
CN Quinazoline, 7-(2-chloroethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 844659-58-1 CAPLUS
CN Quinazoline, 7-(2-chloroethoxy)-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 844659-62-7 CAPLUS
CN Quinazoline, 7-(2-chloroethoxy)-4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 844659-66-1 CAPLUS
CN Quinazoline, 7-(2-chloroethoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 844659-76-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 844659-80-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 844659-85-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 844659-87-6 CAPLUS
CN Ethanone, 2-chloro-1-[4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 844659-88-7 CAPLUS
CN Ethanone, 1-[4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]-2-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 844659-90-1 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-(4-piperidinyloxy)- (CA INDEX NAME)



RN 844659-95-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 844659-97-8 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinyloxy)- (CA INDEX NAME)



RN 844660-01-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 844660-03-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(4-piperidinyloxy)- (CA INDEX NAME)



RN 844660-07-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:99470 CAPLUS
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722 <--
WO 2005009961	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259760	A1	20050203	AU 2004-259760	20040722 <--
CA 2532865	A1	20050203	CA 2004-2532865	20040722 <--
US 20050038080	A1	20050217	US 2004-895985	20040722 <--
EP 1663978	A2	20060607	EP 2004-786091	20040722 <--
EP 1663978	B1	20071128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012219	A	20060822	BR 2004-12219	20040722 <--
CN 1856469	A	20061101	CN 2004-80021091	20040722 <--
JP 2006528196	T	20061214	JP 2006-521221	20040722 <--
ES 2297490	T3	20080501	ES 2004-786091	20040722 <--
ZA 2006000609	A	20070530	ZA 2006-609	20060120 <--
KR 2006052866	A	20060519	KR 2006-701558	20060123 <--
MX 2006000860	A	20060720	MX 2006-860	20060123 <--
IN 2006DN00402	A	20070824	IN 2006-DN402	20060123 <--
NO 2006000870	A	20060407	NO 2006-870	20060222 <--

PRIORITY APPLN. INFO.: US 2003-489102P P 20030723 <--
US 2004-540326P P 20040202
WO 2004-US23500 W 20040722

OTHER SOURCE(S): CASREACT 142:197889
GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g.,

inflammation and as an antiproliferative agent.

IT 288383-20-0, AZD 2171
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:55069 CAPLUS

DOCUMENT NUMBER: 142:127566

TITLE: Cancer combination therapy comprising AZD2171 and ZD1839 and optional ionizing radiation

INVENTOR(S): Wedge, Stephen Robert

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004872	A1	20050120	WO 2004-GB2944	20040708 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004255024	A1	20050120	AU 2004-255024	20040708 <--
CA 2531620	A1	20050120	CA 2004-2531620	20040708 <--
EP 1653964	A1	20060510	EP 2004-743287	20040708 <--
EP 1653964	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1819831	A	20060816	CN 2004-80019517	20040708 <--

CN 100415236	C	20080903			
BR 2004012408	A	20060822	BR 2004-12408	20040708	<--
JP 2007526888	T	20070920	JP 2006-518355	20040708	<--
NZ 544270	A	20070928	NZ 2004-544270	20040708	<--
AT 409039	T	20081015	AT 2004-743287	20040708	<--
ES 2313033	T3	20090301	ES 2004-743287	20040708	<--
NO 2005006170	A	20060208	NO 2005-6170	20051223	<--
US 20060167024	A1	20060727	US 2006-563439	20060105	<--
ZA 2006000184	A	20070425	ZA 2006-184	20060109	<--
MX 2006000412	A	20060317	MX 2006-412	20060110	<--
HK 1089667	A1	20090522	HK 2006-110069	20060911	<--
PRIORITY APPLN. INFO.:			GB 2003-16127 A	20030710	<--
			WO 2004-GB2944 W	20040708	

AB The invention discloses a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor, which comprises the administration of AZD2171 in combination with ZD1839. Also disclosed are a pharmaceutical composition comprising AZD2171 and ZD1839, a combination product comprising AZD2171 and ZD1839 for use in a method of treatment of a human or animal body by therapy, a kit comprising AZD2171 and ZD1839, the use of AZD2171 and ZD1839 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation.

IT 288383-20-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AZD 2171; cancer combination therapy with AZD2171 and ZD1839 and optional ionizing radiation)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



IT 824933-10-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer combination therapy with AZD2171 and ZD1839 and optional ionizing radiation)

RN 824933-10-0 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-, mixt. with 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline (9CI) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 184475-35-2
CMF C22 H24 Cl F N4 O3



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:55068 CAPLUS
DOCUMENT NUMBER: 142:127565
TITLE: AZD2171-ZD6126 combination with optional ionizing radiation for the production of an antiangiogenic and/or vascular permeability-reducing effect and the treatment of cancer
INVENTOR(S): Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004871	A1	20050120	WO 2004-GB2937	20040707 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004255023	A1	20050120	AU 2004-255023	20040707	<--
CA 2531643	A1	20050120	CA 2004-2531643	20040707	<--
EP 1651227	A1	20060503	EP 2004-743280	20040707	<--
EP 1651227	B1	20080213			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

CN 1819830	A	20060816	CN 2004-80019488	20040707	<--
CN 100435799	C	20081126			
BR 2004012450	A	20060919	BR 2004-12450	20040707	<--
JP 2007526887	T	20070920	JP 2006-518354	20040707	<--
AT 385798	T	20080315	AT 2004-743280	20040707	<--
ES 2299841	T3	20080601	ES 2004-743280	20040707	<--
NO 2005006171	A	20060207	NO 2005-6171	20051223	<--
US 20060160775	A1	20060720	US 2006-563440	20060105	<--
ZA 2006000188	A	20070425	ZA 2006-188	20060109	<--
MX 2006000413	A	20060317	MX 2006-413	20060110	<--
HK 1089384	A1	20080620	HK 2006-110018	20060908	<--

PRIORITY APPLN. INFO.:		GB 2003-16123	A	20030710 <--
		WO 2004-GB2937	W	20040707

AB The invention discloses a method for the production of an antiangiogenic and/or vascular permeability-reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor, which comprises the administration of AZD2171 in combination with ZD6126. Also disclosed are a pharmaceutical composition comprising AZD2171 and ZD6126, a combination product comprising AZD2171 and ZD6126 for use in a method of treatment of a human or animal body by therapy, a kit comprising AZD2171 and ZD6126, the use of AZD2171 and ZD6126 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation.

IT 288383-20-0, AZD 2171 824933-09-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AZD2171-ZD6126 combination with optional ionizing radiation for production of antiangiogenic and/or vascular permeability-reducing effect and treatment of cancer)

RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 824933-09-7 CAPLUS

CN Acetamide, N-[(5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo[a,c]cycloheptен-5-yl]-, mixt. with 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline (9CI) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 219923-05-4
CMF C20 H24 N O8 P

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:995977 CAPLUS
DOCUMENT NUMBER: 141:420417
TITLE: Therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis
INVENTOR(S): Curwen, Jon Owen; Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 2004098604         A1     20041118    WO 2004-GB1939          20040504 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004237132         A1     20041118    AU 2004-237132          20040504 <--
     AU 2004237132         B2     20071018
     CA 2519930            A1     20041118    CA 2004-2519930         20040504 <--
     EP 1620104            A1     20060201    EP 2004-731049          20040504 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
     BR 2004009742         A      20060509    BR 2004-9742            20040504 <--
     CN 1784232            A      20060607    CN 2004-80012089        20040504 <--
     CN 100418531          C      20080917
     JP 2006525304         T      20061109    JP 2006-506222          20040504 <--
     NZ 542348             A      20090131    NZ 2004-542348          20040504 <--
     NO 2005004411         A      20051130    NO 2005-4411            20050923 <--
     ZA 2005008858         A      20070328    ZA 2005-8858            20051101 <--
     US 20060223815        A1     20061005    US 2005-555389          20051103 <--
     MX 2005011858         A      20060217    MX 2005-11858           20051104 <--
PRIORITY APPLN. INFO.:                         GB 2003-10401       A   20030507 <--
                                               WO 2004-GB1939      W   20040504

GI
```



I



II

AB The invention relates to the use of an anti-angiogenic agent, such as I (preparation given), in combination with an inhibitor of the Src family of non-receptor tyrosine kinases, such as the II (prepns. according to a previous patent given), in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis. The invention provides for the Src kinase inhibitor to be administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent. Thus, 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline was coupled with 1-acetylpiperazine using KI in DMA to give I. The diastolic blood pressure profile of rats over a 24 h period after administration of a combination of 1.5 mg/kg of I and 25 mg/kg of II demonstrated that the contrasting blood pressure effects of the antiangiogenic agent and the Src kinase inhibitor were substantially counterbalanced.

IT 288383-20-0, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(piperidino)propoxy]quinazoline 288383-22-2, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-26-6, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 574745-20-3, 7-[3-(4-Acetylpiperazin-1-yl)propoxy]-4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxyquinazoline 574745-28-1, 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy]quinazoline 574745-30-5, 7-[2-[4-(2-Fluoroethyl)piperazin-1-yl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 574745-39-4, 4-[(4-Fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-[3-[4-(2-propynyl)piperazin-1-yl]propoxy]quinazoline 574745-40-7, 7-[3-[4-(2-Fluoroethyl)piperazin-1-yl]propoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline 574745-41-8, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazoline
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiogenesis inhibitor; therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis)

RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-21-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288383-22-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288383-23-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288383-26-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 574745-20-3 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-28-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 574745-30-5 CAPLUS
CN Quinazoline, 7-[2-[4-(2-fluoroethyl)-1-piperazinyl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-39-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 574745-40-7 CAPLUS

CN Quinazoline, 7-[3-[4-(2-fluoroethyl)-1-piperazinyl]propoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-41-8 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424 <--
WO 2004096224	A3	20041216		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424 <--
CA 2523868	A1	20041111	CA 2004-2523868	20040424 <--
EP 1622619	A2	20060208	EP 2004-729366	20040424 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424 <--
JP 2006524634	T	20061102	JP 2006-500099	20040424 <--
IN 2005DN04018	A	20091002	IN 2005-DN4018	20050907
MX 2005011656	A	20051215	MX 2005-11656	20051028 <--
NO 2005005605	A	20051128	NO 2005-5605	20051128 <--

PRIORITY APPLN. INFO.:	EP 2003-9587	A	20030429 <--
	EP 2004-508	A	20040113
	EP 2004-1171	A	20040121
	WO 2004-EP4363	W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 288383-20-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:665535 CAPLUS
DOCUMENT NUMBER: 139:358011
TITLE: Topological designing of 4-piperazinylquinazolines as antagonists of PDGFR tyrosine kinase family
AUTHOR(S): Khadikar, Padmakar V.; Shrivastava, Anjali; Agrawal, Vijay K.; Srivastava, Shachi
CORPORATE SOURCE: Research Division, Laxmi Fumigation and Pest Control Pvt. Ltd., Indore, 452 007, India
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 3009-3014
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Topol. designing of a series of 4-piperazinylquinazolines as antagonists of platelet-derived growth factor receptor (PDGFR) tyrosine kinase family has been reported using a series of distance-based topol. indexes. Regression anal. of the data, using maximum R2 method indicated that inhibitory activity, pIC50 (μm), in cellular PGDFR phosphorylation assay can be modeled excellently in multi-parametric model. The results are discussed critically using cross-validated parameters.

IT 401572-16-5 401903-15-9 401950-64-9
401950-72-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topol. designing of 4-piperazinylquinazolines as antagonists of PDGFR tyrosine kinase family and quant. structure-activity relationship studies)

RN 401572-16-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401903-15-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401950-64-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-(1H-indol-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401950-72-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-[(2,3-dihydro-1H-indol-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:633462 CAPLUS
DOCUMENT NUMBER: 139:159941
TITLE: Use of indole-3-acetic acid derivatives in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and other diseases
INVENTOR(S): Baxter, Andrew; Steele, John; Teague, Simon
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066046	A1	20030814	WO 2003-SE184	20030204 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003206310	A1	20030902	AU 2003-206310		20030204	<--
EP 1474136	A1	20041110	EP 2003-703600		20030204	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
JP 2005521675	T	20050721	JP 2003-565470		20030204	<--
US 20050165033	A1	20050728	US 2004-503708		20040805	<--
PRIORITY APPLN. INFO.:			SE 2002-356	A	20020205	<--
			WO 2003-SE184	W	20030204	<--

OTHER SOURCE(S): MARPAT 139:159941

AB The invention discloses 1-(quinazolin-4-yl)- and 1-(quinolin-4-yl)indole-3-acetic acid derivs. and their use in the treatment of respiratory diseases, e.g. asthma, rhinitis, and chronic obstructive pulmonary disease (COPD); and other diseases mediated by prostaglandin D2.

IT 41799-83-1 41799-92-2 577692-63-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indoleacetic acid derivs. for treatment of asthma, chronic obstructive pulmonary disease, and other diseases)

RN 41799-83-1 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(4-quinazolinyl)- (CA INDEX NAME)



RN 41799-92-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 577692-63-8 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-2-methyl-5-(2-methylpropoxy)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:610442 CAPLUS
DOCUMENT NUMBER: 139:164806
TITLE: Preparation of quinazolines as VEGF receptor inhibitors
INVENTOR(S): Hennequin, Laurent Francois Andre
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064413	A1	20030807	WO 2003-GB343	20030128 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473572	A1	20030807	CA 2003-2473572	20030128 <--
EP 1474420	A1	20041110	EP 2003-700951	20030128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007151	A	20041207	BR 2003-7151	20030128 <--
HU 2004002588	A2	20050530	HU 2004-2588	20030128 <--
HU 2004002588	A3	20090928		
CN 1625555	A	20050608	CN 2003-803124	20030128 <--
JP 2005522428	T	20050728	JP 2003-564036	20030128 <--
NZ 534171	A	20070629	NZ 2003-534171	20030128 <--
RU 2362774	C1	20090727	RU 2008-100766	20030128 <--
RU 2362775	C1	20090727	RU 2008-100767	20030128 <--
RU 2365588	C2	20090827	RU 2004-126612	20030128 <--

AU 2003202094	B2	20091008	AU 2003-202094		20030128 <--
IN 2004DN02016	A	20050401	IN 2004-DN2016		20040714 <--
NO 2004003162	A	20040722	NO 2004-3162		20040722 <--
ZA 2004005908	A	20050926	ZA 2004-5908		20040723 <--
US 20050085465	A1	20050421	US 2004-502538		20040728 <--
US 7268230	B2	20070911			
MX 2004007459	A	20050908	MX 2004-7459		20040730 <--
US 20080027069	A1	20080131	US 2007-705035		20070212 <--
US 20090156821	A1	20090618	US 2007-882604		20070802 <--
PRIORITY APPLN. INFO.:			EP 2002-290242	A	20020201 <--
			RU 2004-126612	A3	20030128 <--
			WO 2003-GB343	W	20030128 <--
			US 2004-502538	A1	20040728

OTHER SOURCE(S): CASREACT 139:164806; MARPAT 139:164806

GI



I



II

AB The title compds. [I; ring C = indolyl, indazolyl or azaindolyl; Z = O, NH, S; n = 0-5; m = 0-3; R2 = H, OH, halo, etc.; R1 = H, halo, oxo, OH, etc.], useful in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepared and formulated. E.g., a multi-step synthesis of II, was given. The compds. I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis (no biol. data).

IT 574745-14-5P 574745-15-6P 574745-16-7P
574745-17-8P 574745-18-9P 574745-19-0P
574745-20-3P 574745-21-4P 574745-22-5P
574745-23-6P 574745-24-7P 574745-25-8P
574745-26-9P 574745-27-0P 574745-28-1P
574745-29-2P 574745-30-5P 574745-31-6P
574745-32-7P 574745-33-8P 574745-34-9P
574745-35-0P 574745-36-1P 574745-37-2P
574745-38-3P 574745-39-4P 574745-40-7P

574745-41-8P 574745-43-0P 574745-44-1P
574745-45-2P 574745-47-4P 574745-48-5P
574745-49-6P 574745-50-9P 574745-51-0P
574745-52-1P 574745-53-2P 574745-54-3P
574745-55-4P 574745-56-5P 574745-57-6P
574745-58-7P 574745-59-8P 574745-61-2P
574745-62-3P 574745-63-4P 574745-64-5P
574745-65-6P 574745-66-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolines as VEGF inhibitors)

RN 574745-14-5 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-15-6 CAPLUS
CN Quinazoline, 7-methoxy-6-[3-[4-(methylsulfonyl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-16-7 CAPLUS
CN Ethanone, 1-[4-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-6-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-17-8 CAPLUS
CN Ethanone, 1-[4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-

quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-18-9 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-[4-(methylsulfonyl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-19-0 CAPLUS
CN 2-Propyn-1-amine, N-[2-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 574745-20-3 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-21-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy-6-[3-[4-(methylsulfonyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 574745-22-5 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(methylsulfonyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 574745-23-6 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-24-7 CAPLUS
CN Ethanone, 1-[4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-

quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 574745-25-8 CAPLUS
CN Ethanone, 1-[(2S)-2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-26-9 CAPLUS
CN Ethanone, 1-[(2R)-2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-27-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[[1-(2,2,2-trifluoroethyl)-4-piperidinyl]methoxy]- (CA INDEX NAME)



RN 574745-28-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 574745-29-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]ethoxy]- (CA INDEX NAME)



RN 574745-30-5 CAPLUS
CN Quinazoline, 7-[2-[4-(2-fluoroethyl)-1-piperazinyl]ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-31-6 CAPLUS
CN Ethanone, 1-[4-[2-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-

7-quinazolinyl]oxy]ethoxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-32-7 CAPLUS
CN 1-Propanone, 1-[4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 574745-33-8 CAPLUS
CN 1-Propanone, 1-[(2S)-2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-pyrrolidinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-34-9 CAPLUS
CN 1-Propanone, 1-[(2R)-2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-pyrrolidinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-35-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- (CA INDEX NAME)



RN 574745-36-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[[(2S)-1-(methylsulfonyl)-2-pyrrolidinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-37-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[[(2R)-1-(methylsulfonyl)-2-pyrrolidinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-38-3 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-[4-(2-propen-1-yl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-39-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 574745-40-7 CAPLUS
CN Quinazoline, 7-[3-[4-(2-fluoroethyl)-1-piperazinyl]propoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-41-8 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-43-0 CAPLUS
CN Ethanone, 1-[4-[3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-44-1 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-45-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (CA INDEX NAME)



RN 574745-47-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (CA INDEX NAME)



RN 574745-48-5 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-5-(1-hydroxy-1-methylethyl)- (CA INDEX NAME)



RN 574745-49-6 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-50-9 CAPLUS
CN Ethanone, 1-[4-[[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 574745-51-0 CAPLUS
CN Ethanone, 1-[4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 574745-52-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-[[1-(methylsulfonyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



RN 574745-53-2 CAPLUS
CN 2-Propyn-1-amine, N-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 574745-54-3 CAPLUS
CN Ethanone, 1-[4-[2-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-55-4 CAPLUS
CN Ethanone, 1-[4-[3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-56-5 CAPLUS
CN Ethanone, 1-[4-[3-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-1-piperazinyl]- (CA INDEX NAME)



RN 574745-57-6 CAPLUS
CN 1-Piperazineacetamide, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (CA INDEX NAME)



RN 574745-58-7 CAPLUS
CN 1-Piperazineacetamide, 4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (CA INDEX NAME)



RN 574745-59-8 CAPLUS
CN Quinazoline, 7-[3-[4-(2-fluoroethyl)-1-piperazinyl]propoxy]-6-methoxy-4-

[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 574745-61-2 CAPLUS
CN 1-Piperazineethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(2-propyn-1-yl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-62-3 CAPLUS
CN Quinazoline, 7-[2-[4-(2-fluoroethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-63-4 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-64-5 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane-8-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-65-6 CAPLUS
CN Ethanone, 1-[4-[(2R)-3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-66-7 CAPLUS
CN Ethanone, 2-(dimethylamino)-1-[4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-piperidinyl]- (CA INDEX

NAME)



IT 288387-52-0 574746-13-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolines as VEGF inhibitors)
RN 288387-52-0 CAPLUS
CN Quinazoline, 7-(3-bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (CA INDEX NAME)



RN 574746-13-7 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)



IT 574745-67-8P 574745-68-9P 574745-69-0P
574745-70-3P 574745-75-8P 574745-76-9P
574745-77-0P 574745-79-2P 574745-80-5P
574745-81-6P 574745-82-7P 574745-83-8P
574745-84-9P 574745-85-0P 574745-86-1P
574745-87-2P 574745-88-3P 574745-89-4P
574745-90-7P 574745-92-9P 574745-99-6P
574746-00-2P 574746-03-5P 574746-04-6P
574746-05-7P 574746-06-8P 574746-08-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolines as VEGF inhibitors)
RN 574745-67-8 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy-6-(phenylmethoxy)- (CA INDEX NAME)



RN 574745-68-9 CAPLUS
CN 6-Quinazolinol, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy- (CA INDEX NAME)



RN 574745-69-0 CAPLUS
CN Quinazoline, 7-methoxy-6-(phenylmethoxy)-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-70-3 CAPLUS
CN 6-Quinazolinol, 7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574745-75-8 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(phenylmethoxy)- (CA INDEX NAME)



RN 574745-76-9 CAPLUS
CN 7-Quinazolinol, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-77-0 CAPLUS
CN Quinazoline, 7-(3-bromopropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-79-2 CAPLUS
CN Quinazoline, 6-(3-bromopropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-methoxy- (CA INDEX NAME)



RN 574745-80-5 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(phenylmethoxy)- (CA INDEX NAME)



RN 574745-81-6 CAPLUS
CN 6-Quinazolinol, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy- (CA INDEX NAME)



RN 574745-82-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 574745-83-8 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 574745-84-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-85-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(2S)-2-pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-86-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-87-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(2R)-2-pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 574745-88-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 574745-89-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 574745-90-7 CAPLUS
CN Quinazoline, 7-(2-bromoethoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-92-9 CAPLUS
CN Quinazoline, 7-[2-(2-bromoethoxy)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 574745-99-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 574746-00-2 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 574746-03-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 574746-04-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 574746-05-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 574746-06-8 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(4-piperidinyloxy)- (CA INDEX NAME)



RN 574746-08-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(2R)-2-oxiranylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:532545 CAPLUS
DOCUMENT NUMBER: 139:95455
TITLE: Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
INVENTOR(S): Geroni, Maria Cristina; Fowst, Camilla; Cozzi, Paolo
PATENT ASSIGNEE(S): Pharmacia Italia SpA, Italy

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055522	A1	20030710	WO 2002-EP13092	20021218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472008	A1	20030710	CA 2002-2472008	20021218 <--
CA 2472008	C	20090728		
AU 2002352090	A1	20030715	AU 2002-352090	20021218 <--
AU 2002352090	B2	20080515		
EP 1461083	A1	20040929	EP 2002-787763	20021218 <--
EP 1461083	B1	20060329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015454	A	20041123	BR 2002-15454	20021218 <--
HU 2004002639	A2	20050428	HU 2004-2639	20021218 <--
CN 1617744	A	20050518	CN 2002-827674	20021218 <--
JP 2005516025	T	20050602	JP 2003-556098	20021218 <--
AT 321572	T	20060415	AT 2002-787763	20021218 <--
ES 2263835	T3	20061216	ES 2002-787763	20021218 <--
NZ 533854	A	20070531	NZ 2002-533854	20021218 <--
RU 2328306	C2	20080710	RU 2004-123641	20021218 <--
MX 2004006543	A	20041004	MX 2004-6543	20040702 <--
ZA 2004005290	A	20050617	ZA 2004-5290	20040702 <--
IN 2004DN01960	A	20090403	IN 2004-DN1960	20040708 <--
NO 2004003217	A	20040730	NO 2004-3217	20040729 <--
US 20060084612	A1	20060420	US 2005-500606	20050505 <--
IN 2007DN00991	A	20070803	IN 2007-DN991	20070206 <--

PRIORITY APPLN. INFO.:		EP 2002-75052	A	20020102 <--
		WO 2002-EP13092	W	20021218 <--
		IN 2004-DN1960	A3	20040708

OTHER SOURCE(S): MARPAT 139:95455
GI



AB The present invention provides the combined use of acryloyl distamycin derivs., in particular α-bromo- and α-chloro-acryloyl distamycin derivs., and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis. An example protein kinase inhibitor is STI 571 and a distamycin derivative is brostallicin (I).

IT 288383-20-0, ZD 2171
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined antitumor therapy comprising acryloyl distamycin derivs. and protein kinase (serine/threonine kinase) inhibitors)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:532526 CAPLUS

DOCUMENT NUMBER: 139:101024

TITLE: Preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compositions for treatment of neurodegenerative diseases

INVENTOR(S): Berg, Stefan; Bhat, Ratan; Edwards, Philip; Hellberg, Sven

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003055492	A1	20030710	WO 2002-SE2370		20021218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002359161	A1	20030715	AU 2002-359161		20021218 <--
EP 1458394	A1	20040922	EP 2002-793675		20021218 <--
EP 1458394	B1	20081022			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005516960	T	20050609	JP 2003-556069		20021218 <--
AT 411801	T	20081115	AT 2002-793675		20021218 <--
ES 2314123	T3	20090316	ES 2002-793675		20021218 <--
US 20050070559	A1	20050331	US 2004-499950		20041112 <--
PRIORITY APPLN. INFO.:			US 2001-344887P	P	20011221 <--
			WO 2002-SE2370	W	20021218 <--

OTHER SOURCE(S): MARPAT 139:101024

GI



I



II

AB 2-Oxindoles, such as I [R = substituted- or unsubstituted-quinazolin-4-yl; R2 = OH, CH2F, CF3, OCF3, CN, NH2, NO2, alkyl, alkoxy, acyloxy, acyl, alkylthio, etc.; m = 0-4], were prepared for therapeutic use as GSK3 inhibitors. These oxindoles are intended for therapeutic use in the treatment of GSK3 associated diseases, such as Alzheimer's disease, dementia, Parkinson dementia complex of Guam, frontotemporal dementia Parkinson's type, HIV dementia, neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, dementia pugilistic and age

related cognitive disorders, as well as for male contraception and treatment of diabetes, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's disease, Parkinson's disease, postencephelatic Parkinsonism, progressive supranuclear palsy, Pick's disease, Niemann-Pick's disease, stroke, head trauma, bipolar disease, affective disorders, depression, schizophrenia, cognitive disorders and androgenetic alopecia. Thus, the dihydrochloride salt of oxindole II was prepared in 68% yield by a coupling reaction of 5-cyanooxindole with 4-chloro-7-(2-morpholinoethoxy)quinazoline in DMF using NaH. The prepared oxindoles were tested for GSK3 inhibition using the GSK3β proximity assay.

IT 557093-01-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-oxindole derivs. as glycogen synthase kinase-3 (GSK3) inhibitors for use in pharmaceutical compns. for treatment of neurodegenerative diseases)

RN 557093-01-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]-2-oxo-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 557093-00-2
CMF C22 H20 N6 O5 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:548513 CAPLUS
DOCUMENT NUMBER: 137:288493
TITLE: Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family

AUTHOR(S): Pandey, Anjali; Volkots, Deborah L.; Seroogy, Joseph M.; Rose, Jack W.; Yu, Jin-Chen; Lambing, Joseph L.; Hutchaleelaha, Athiwat; Hollenbach, Stanley J.; Abe, Keith; Giese, Neill A.; Scarborough, Robert M.
CORPORATE SOURCE: Medicinal Chemistry Department, Biology Department, Drug Metabolism Pharmacokinetic Department and In Vivo Sciences, Millennium Pharmaceuticals Inc., South San Francisco, CA, 94080, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(17), 3772-3793
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:288493
AB We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation. A series of highly potent, specific, orally active, small mol. kinase inhibitors directed against members of PDGFR receptor have been developed through modifications of the novel quinazoline template I. Systematic modifications in the A-bicyclic ring and D-rings of pro-type I were carried out to afford potent analogs, which display IC50 values of <250 nM in cellular βPDGFR phosphorylation assays. An optimized analog in this series, 75 (CT53518), inhibits Flt-3, βPDGFR, and c-Kit receptor phosphorylation with IC50 values of 50-200 nM, whereas 15-20-fold less potent activity against CSF-1R was observed This analog also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC50 values of 30-100 nM. Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T1/2 > 8 h). Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.
IT 401572-16-5P 401903-15-9P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(oral bioavailability, pharmacokinetics and selectivity of 4-piperazinylquinazolines as antagonists of the PDGFR tyrosine kinase family)
RN 401572-16-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401903-15-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 401950-64-9P 401950-72-9P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oral bioavailability, pharmacokinetics and selectivity of 4-piperazinylquinazolines as antagonists of the PDGFR tyrosine kinase family)

RN 401950-64-9 CAPLUS

CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-(1H-indol-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401950-72-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-[(2,3-dihydro-1H-indol-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 63 THERE ARE 63 CAPLUS RECORDS THAT CITE THIS RECORD (64 CITINGS)
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:157774 CAPLUS
DOCUMENT NUMBER: 136:200202
TITLE: Preparation of 4-[4-(phenylcarbamoyl)piperazino]quinazolines as PDGF receptor phosphorylation inhibitors
INVENTOR(S): Pandey, Anjali; Scarborough, Robert M.; Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji
PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA; Kyowa Hakko Kogyo Co., Ltd.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2002016362	A2	20020228	WO 2001-US41751		20010817	<--
WO 2002016362	A3	20020613				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
AU 2001093209	A	20020304	AU 2001-93209		20010817	<--
EP 1309569	A2	20030514	EP 2001-973654		20010817	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
US 20040186110	A1	20040923	US 2004-344737		20040318	<--
US 6956039	B2	20051018				
US 20060063770	A1	20060323	US 2005-200456		20050808	<--
PRIORITY APPLN. INFO.:			US 2000-226089P	P	20000818	<--
			WO 2001-US41751	W	20010817	<--
			US 2004-344737	A3	20040318	

OTHER SOURCE(S): MARPAT 136:200202

AB Title compds., e.g., R2OZZ1CONHC6H4R1-4 (Z = quinazoline-7,4-diyl; Z1 = piperazine-1,4-diyl)(I; R1 = cyano, alkoxy, indolyloxy, etc.; R2 = 2-morpholinoethyl, 2-pyrrolidinoethyl, MeOCH2CH2, etc.) were prepared Thus, 4,2-F(H2N)C6H3CO2Et (preparation given) was cyclocondensed with HCO2NH4 and the product etherified by 2-piperidinoethanol to give, in 3 addnl. steps, I (R1 = cyano, R2 = 2-piperidinoethyl). Data for biol. activity of I were given.

IT 401572-16-5P 401572-20-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-[4-(phenylcarbamoyl)piperazino]quinazolines as PDGF receptor phosphorylation inhibitors)

RN 401572-16-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401572-20-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[7-(3-methoxypropoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:157772 CAPLUS
DOCUMENT NUMBER: 136:216768
TITLE: Preparation of piperazinyl quinazolines for inhibiting phosphorylation of PDGF receptor
INVENTOR(S): Pandey, Anjali; Scarborough, Robert M.; Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji
PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA; Kyowa Hakko Kogyo Co., Ltd.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016360	A2	20020228	WO 2001-US41749	20010817 <--
WO 2002016360	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001093207	A	20020304	AU 2001-93207	20010817 <--
EP 1309567	A2	20030514	EP 2001-973652	20010817 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040259881	A1	20041223	US 2004-344907	20040401 <--
PRIORITY APPLN. INFO.:			US 2000-266120P P	20000818 <--
			US 2001-266120P P	20010202 <--
			WO 2001-US41749 W	20010817 <--

OTHER SOURCE(S): MARPAT 136:216768

GI



I

AB The title compds. [I; m, n = 2-8; X = O, S; R = CN, CMe3, 5-hydroxyindol-1-yl, etc.; R1, R2 = OH, OMe, C(:NH)NH2, etc.] which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and therefore useful for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis, were prepared Thus, reacting 6,7-bis(2-methoxyethoxy)-4-piperazinylquinazoline (preparation given) with 4-cyanophenyl isocyanate in DMF afforded 73% I [n, m = 2; R1, R2 = OMe; X = O; R = CN] which showed IC50 of 0.615 μM in MG63 phosphorylation assay.

IT 401950-60-5P 401950-64-9P 401950-65-0P
401950-72-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinyl quinazolines for inhibiting phosphorylation of PDGF receptor)

RN 401950-60-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-(5-hydroxy-1H-indol-1-yl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401950-64-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-(1H-indol-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401950-65-0 CAPLUS
CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-(1H-indol-5-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401950-72-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]-N-[4-[(2,3-dihydro-1H-indol-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:157763 CAPLUS
DOCUMENT NUMBER: 136:216753
TITLE: Preparation of 4-quinazolinyl-1-piperazinecarboxamides as kinase inhibitors for treatment of proliferative diseases
INVENTOR(S): Pandey, Anjali; Scarborough, Robert M.; Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji
PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA; Kyowa Hakko Kogyo Co., Ltd.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016351	A1	20020228	WO 2001-US41752	20010817 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2426440	A1	20020228	CA 2001-2426440	20010817 <--
AU 2001085449	A	20020304	AU 2001-85449	20010817 <--
EP 1315715	A1	20030604	EP 2001-964612	20010817 <--
EP 1315715	B1	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002615	A2	20031229	HU 2003-2615	20010817 <--
HU 2003002615	A3	20080328		
BR 2001013356	A	20040420	BR 2001-13356	20010817 <--
NZ 524461	A	20041224	NZ 2001-524461	20010817 <--
JP 2005501796	T	20050120	JP 2002-521452	20010817 <--
CN 1633431	A	20050629	CN 2001-817352	20010817 <--
CN 100358890	C	20080102		
AU 2001285449	B2	20070405	AU 2001-285449	20010817 <--
AT 402169	T	20080815	AT 2001-964612	20010817 <--
EP 1964839	A2	20080903	EP 2008-75237	20010817 <--
EP 1964839	A3	20081105		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
ES 2311023	T3	20090201	ES 2001-964612	20010817 <--
MX 2003001359	A	20041213	MX 2003-1359	20030213 <--
NO 2003000747	A	20030414	NO 2003-747	20030217 <--
NO 323782	B1	20070702		
KR 831116	B1	20080520	KR 2003-702381	20030218 <--
ZA 2003001510	A	20040622	ZA 2003-1510	20030226 <--
IN 2003DN00233	A	20070309	IN 2003-DN233	20030226 <--
US 20050101609	A1	20050512	US 2003-344736	20031016 <--
US 6982266	B2	20060103		
HK 1057206	A1	20081224	HK 2003-108720	20031128 <--
US 20050288297	A1	20051229	US 2005-210028	20050822 <--
US 7560461	B2	20090714		

PRIORITY APPLN. INFO.:	US 2000-226122P	P	20000818 <--
	EP 2001-964612	A3	20010817 <--
	US 2003-344736	A1	20010817 <--
	WO 2001-US41752	W	20010817 <--

OTHER SOURCE(S): MARPAT 136:216753

GI



I

AB Title compds. I [wherein R1 = CN, halo, trihalomethyl, R5, CO2R5, SO2R5, alkoxy, phenoxy, naphthyloxy, indolyloxy, or isoquinolinyloxy; R2 and R4 = independently OMe, OEt, OCH2CH:CH2, OCH2C.tplbond.CH, O(CH2)nSO2R5, OCH2CHR6CH2R3, or O(CH2)nR3; R3 = OH, OMe, OEt, NH2, NMe2, NHCH2Ph, NHPh, CN, C(NH)NH2, NHC(NH)NH2, thiazolyl, oxazolyl, (difluoro)pyrrolidinyl, (difluoro)piperidinyl, morpholinyl, imidazolyl, triazolyl, thiomorpholinyl, pyridinyloxy, tetrazolyl, piperazinyl, etc.; R5 = H or alkyl; R6 = OH, halo, or alkyl; n = 2-3; or pharmaceutically acceptable isomers, salts, hydrates, solvates, and prodrug derivs. thereof], which have inhibitory activity on the phosphorylation of platelet-derived growth factor (PDGF), were prepared For example, vanillic acid was protected with benzyl bromide (96%), treated with HNO3 to give the nitro derivative (96.5%), reduced to the amine with SnCl2•H2O, and cyclized with formamide to gave 7-benzyloxy-6-methoxy-4-quinazolinone (81%). Chlorination (62%), followed by substituted with Boc-piperazine (81%), debenzylation (98%), coupling with 1-chloroethyl tosylate (40%), addition of piperidine (55%), deprotection using 4N HCl/dioxane and amidation with 4-cyanophenylisocyanate (59%), afforded the quinazoline I [R1 = CN; R2 = 2-piperidinoethoxy; R4 = OMe] (II). The latter inhibited β-PDGFR phosphorylation in the HR5 cell line and MG63 human osteosarcoma tumor cell line with IC50 values of 0.360 μM and 0.080 μM, resp. I hinder abnormal cell growth and cell wandering and are useful for the prevention or treatment of cell-proliferative diseases, such as arteriosclerosis, vascular reobstruction, cancer, and glomerulosclerosis.

IT 401903-15-9P, N-(4-Indol-5-yloxyphenyl)-4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]-1-piperazinecarboxamide
401903-20-6P, N-(4-Indol-4-yloxyphenyl)[4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl]carboxamide
401903-93-3P, [4-(7-Ethoxy-6-methoxyquinazolin-4-yl)piperazinyl]-N-(4-indol-4-yloxyphenyl)carboxamide 401904-04-9P
401904-53-8P, N-(4-Indol-4-yloxyphenyl)[4-(6-Methoxy-7-prop-2-ynyloxyquinazolin-4-yl)piperazinyl]carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDGF inhibitor; preparation of quinazolinylpiperazinecarboxamides as PDGF receptor phosphorylation inhibitors for treatment of proliferative diseases)

RN 401903-15-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[4-(1H-indol-5-yloxy)phenyl]-4-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401903-20-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-4-yloxy)phenyl]-4-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401903-93-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-(7-ethoxy-6-methoxy-4-quinazolinyl)-N-[4-(1H-indol-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401904-04-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-4-yloxy)phenyl]-4-[6-methoxy-7-(2-propen-1-yloxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 401904-53-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-(1H-indol-4-yloxy)phenyl]-4-[6-methoxy-7-(2-propyn-1-yloxy)-4-quinazolinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:10442 CAPLUS
DOCUMENT NUMBER: 136:85762
TITLE: New aryl-, quinolyl-, and other heterocyclyl-containing amino alcohol derivatives useful as β3 adrenergic receptor agonists
INVENTOR(S): Kayakiri, Hiroshi; Sakurai, Minoru; Washizuka, Kenichi; Hamashima, Hitoshi; Tomishima, Yasuyo; Fujii, Naoaki; Taniguchi, Kiyoshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002000622 A2 20020103 WO 2001-JP5425 20010625 <--
WO 2002000622 A3 20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: AU 2000-8413 A 20000627 <--
OTHER SOURCE(S): MARPAT 136:85762
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I [wherein: X1 = bond or OCH2; X2 = (CH2)1-2; X3 = bond, O, or NH; R1 = (un)substituted Ph, indolyl, or carbazolyl [substituents = 1 or 2 of OH, halo, NO2, amino, formyl, (lower)alkylsulfonylamino, aryl(lower)alkoxy, and hydroxy(lower)alkyl]; R2 = H or aryl(lower)alkyl; R3 = H or hydroxy(lower)alkyl; R4 = (un)substituted aryl, 4-quinolyl, phthalazinyl, quinazolinyl, cinnolinyl, or naphthyridinyl; with provisos], or their pharmaceutically acceptable salts. The compds. are β3 adrenergic receptor agonists, and therefore have gut sympathomimetic, antiulcer, anti-pancreatitis, lipolytic, and smooth muscle relaxant activities. In particular, I and salts are useful for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence. Sixty precursor prepns. and 63 invention examples, including well over 200 invention compds., are provided. For example, the structure of claimed compound II is typical. Another invention compound, phthalazine derivative III, was prepared from 4-((2S)-2-amino-3-hydroxypropyl)phenol HCl, benzaldehyde, (2S)-3-phenoxy-1,2-epoxypropane, and 1-chlorophthalazine, in 4 steps. III at 0.32 mg/kg (intraduodenal) in beagle dogs gave 35.9% inhibition of carbachol-induced increase in intravesical pressure.
IT 386209-31-0P, (2S)-2-[N-[(2S)-2-Hydroxy-3-(4-1H-indolyloxy)propyl]amino]-3-[4-(4-quinazolinyloxy)phenyl]propan-1-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl- and quinolyl-containing amino alcs. and
analogs as β3-adrenergic receptor agonists)
RN 386209-31-0 CAPLUS
CN Benzenepropanol, β-[[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-4-(4-quinazolinyloxy)-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:747609 CAPLUS
DOCUMENT NUMBER: 135:283196
TITLE: Therapeutic combinations of antihypertensive and antiangiogenic agents
INVENTOR(S): Curwen, Jon Owen; Ogilvie, Donald James
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074360	A1	20011011	WO 2001-GB1522	20010402 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401854	A1	20011011	CA 2001-2401854	20010402 <--
EP 1272186	A1	20030108	EP 2001-917305	20010402 <--
EP 1272186	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009729	A	20030204	BR 2001-9729	20010402 <--
HU 2003000426	A2	20030628	HU 2003-426	20010402 <--
JP 2003528917	T	20030930	JP 2001-572104	20010402 <--
EE 200200578	A	20040615	EE 2002-578	20010402 <--
AU 2001244386	B2	20050127	AU 2001-244386	20010402 <--
NZ 520938	A	20050826	NZ 2001-520938	20010402 <--

AT 355065	T	20060315	AT 2001-917305	20010402	<--
EP 1658849	A2	20060524	EP 2006-3576	20010402	<--
EP 1658849	A3	20090218			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
NZ 534455	A	20070126	NZ 2001-534455	20010402	<--
EP 1790340	A2	20070530	EP 2007-3863	20010402	<--
EP 1790340	A3	20090318			
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI					
ES 2280349	T3	20070916	ES 2001-917305	20010402	<--
CZ 299410	B6	20080716	CZ 2002-3304	20010402	<--
IN 2002MN01149	A	20050304	IN 2002-MN1149	20020823	<--
ZA 2002006959	A	20031201	ZA 2002-6959	20020829	<--
US 20030144298	A1	20030731	US 2002-240413	20021001	<--
KR 849149	B1	20080731	KR 2002-713170	20021002	<--
MX 2002009743	A	20030327	MX 2002-9743	20021003	<--
NO 2002004814	A	20021112	NO 2002-4814	20021004	<--
NO 323467	B1	20070521			
NO 2006002050	A	20011008	NO 2006-2050	20060508	<--
NO 326277	B1	20081027			
KR 2008034523	A	20080421	KR 2008-707835	20080331	<--

PRIORITY APPLN. INFO.:	GB 2000-8269	A	20000405 <--
	EP 2001-917305	A3	20010402 <--
	NZ 2001-520938	A1	20010402 <--
	WO 2001-GB1522	W	20010402 <--
	KR 2002-713170	A3	20021002 <--

OTHER SOURCE(S): MARPAT 135:283196

AB The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manufacture of a medicament for the treatment of a disease state associated with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compns. comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state associated with angiogenesis which comprises the administration of an effective amount of a combination of an anti-angiogenic agent and an anti-hypertensive agent to a warm-blooded animal, such as a human being. Anesthetized rats were dosed orally with 12.5 mg/kg of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline for 10 days, then they were dosed orally with 30 mg/kg captopril in addition to quinazoline compound The increase in diastolic blood pressure was reversed by the addition of captopril.

IT 288383-14-2 288383-15-3 288383-16-4
288383-17-5 288383-18-6 288383-19-7
288383-20-0 288383-21-1 288383-22-2
288383-23-3 288383-24-4 288383-25-5
288383-26-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations of antihypertensive and antiangiogenic agents)

RN 288383-14-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-15-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288383-16-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288383-17-5 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-18-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-

pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-19-7 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-21-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288383-22-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288383-23-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288383-24-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288383-25-5 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-26-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:78383 CAPLUS
DOCUMENT NUMBER: 134:163059
TITLE: Substituted piperazinone derivatives and other oxoazaheterocyclyl compounds useful as factor Xa/IIa inhibitors
INVENTOR(S): Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen; Myers, Michael R.; Lau, Wan F.; Poli, Gregory B.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
SOURCE: PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007436	A2	20010201	WO 2000-IB1156	20000726 <--
WO 2001007436	A3	20010823		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,

CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CA 2382755	A1	20010201	CA 2000-2382755		20000726 <--
BR 2000013179	A	20020402	BR 2000-13179		20000726 <--
EP 1208097	A2	20020529	EP 2000-951781		20000726 <--
EP 1208097	B1	20090218			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

TR 200200225	T2	20020621	TR 2002-225		20000726 <--
HU 2002003375	A2	20021228	HU 2002-3375		20000726 <--
HU 2002003375	A3	20050329			
JP 2003508353	T	20030304	JP 2001-512520		20000726 <--
EE 200200045	A	20030616	EE 2002-45		20000726 <--
AU 773227	B2	20040520	AU 2000-64628		20000726 <--
IL 147495	A	20070724	IL 2000-147495		20000726 <--
AT 423113	T	20090315	AT 2000-951781		20000726 <--
NO 2002000214	A	20020402	NO 2002-214		20020115 <--
BG 106340	A	20021031	BG 2002-106340		20020122 <--
ZA 2002000543	A	20030623	ZA 2002-543		20020122 <--
MX 2002000888	A	20020730	MX 2002-888		20020125 <--
PRIORITY APPLN. INFO.:			US 1999-363196	A	19990728 <--
			WO 2000-IB1156	W	20000726 <--

OTHER SOURCE(S): MARPAT 134:163059

GI



I



II

AB The invention is directed to piperazinones I and their pharmaceutically acceptable salts, prodrugs, N-oxides, hydrates, and solvates [wherein A = CH or N; G1 and G2 = L1Cy1 or L2Cy2; Cy1 and Cy2 = (un)substituted aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, etc.; L1 = null, O, S, SO, SO2, or (un)substituted sulfamoyl, methylene, (alkyl)keto(alkyl), carbamoyl, etc.; L2 = null or linking group; R1, R1a, R2, R2a, R3, R3a, R4, R4a = independently H, carboxy, alkoxycarbonyl, alkyl, (hetero)aryl, aralkyl, heteroarylalkyl, etc.; m and n = independently 0-2]. The compds. inhibit factor Xa (no data) and factor IIa, and thereby the production of

thrombin, and are thus useful as anticoagulants in the treatment of a wide variety of conditions. The invention is also directed to pharmaceutical compns., synthetic intermediates, and a method of inhibiting factor Xa. Examples include the synthesis of approx. 1600 invention compds. and several hundred intermediates. For instance, condensation of 5-chloro-2-thienyloxyacetic acid with the corresponding N-benzyloxycarbonyl-protected piperazinone derivative (prepns. given), using DIPEA and TBTU in DMF, gave II.

IT 323583-79-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of piperazinone derivs. and other substituted oxoazaheterocyclyl compds. as factor Xa/IIa inhibitors)

RN 323583-79-5 CAPLUS

CN 2-Piperazinone, 1-[(4-amino-7-quinazolinyl)methyl]-4-[(5-hydroxy-1H-indol-2-yl)carbonyl]-3-propyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:573671 CAPLUS
DOCUMENT NUMBER: 133:177183
TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors
INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.
SOURCE: PCT Int. Appl., 346 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	A1	20000817	CA 2000-2362715	20000208 <--
CA 2674803	A1	20000817	CA 2000-2674803	20000208 <--

```
     EP 1154774           A1    20011121    EP 2000-902730         20000208 <--
     EP 1154774           B1    20050622
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     TR 200102314         T2    20020121    TR 2001-2314           20000208 <--
     BR 2000008128        A     20020213    BR 2000-8128           20000208 <--
     HU 2001004964        A2    20020429    HU 2001-4964           20000208 <--
     HU 2001004964        A3    20030228
     JP 2002536414        T     20021029    JP 2000-598164         20000208 <--
     JP 3893026           B2    20070314
     EE 200100409         A     20021216    EE 2001-409            20000208 <--
     AU 763618            B2    20030731    AU 2000-24475          20000208 <--
     NZ 513204            A     20040430    NZ 2000-513204         20000208 <--
     CN 1167422           C     20040922    CN 2000-806085         20000208 <--
     CN 1597667           A     20050323    CN 2004-10058982       20000208 <--
     CN 100360505         C     20080109
     TR 200500745         T2    20050523    TR 2005-745            20000208 <--
     NZ 530832            A     20050527    NZ 2000-530832         20000208 <--
     EP 1553097           A1    20050713    EP 2005-4285           20000208 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     AT 298237            T     20050715    AT 2000-902730         20000208 <--
     RU 2262935           C2    20051027    RU 2001-124816         20000208 <--
     ES 2242596           T3    20051116    ES 2000-902730         20000208 <--
     IL 144745            A     20081103    IL 2000-144745         20000208 <--
     EP 2050744           A1    20090422    EP 2008-168638         20000208 <--
         R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
             NL, PT, SE, AL, LT, LV, MK, RO, SI
     IN 2000DE00115       A     20050311    IN 2000-DE115          20000211 <--
     IN 2001MN00893       A     20070525    IN 2001-MN893          20010726 <--
     ZA 2001006340        A     20021101    ZA 2001-6340           20010801 <--
     NO 2001003882        A     20011009    NO 2001-3882           20010809 <--
     NO 321604            B1    20060612
     MX 2001008182        A     20030820    MX 2001-8182           20010810 <--
     KR 838617            B1    20080616    KR 2001-710133         20010810 <--
     HK 1041212           A1    20051202    HK 2002-102781         20020412 <--
     US 7074800           B1    20060711    US 2002-913020         20020506 <--
     NO 2005002773        A     20011009    NO 2005-2773           20050608 <--
     US 20060004017       A1    20060105    US 2005-169122         20050629 <--
     HK 1076104           A1    20081031    HK 2005-108262         20050921 <--
     JP 2006273860        A     20061012    JP 2006-129249         20060508 <--
     KR 2008015482        A     20080219    KR 2007-731001         20071231 <--
PRIORITY APPLN. INFO.:                       EP 1999-400305      A  19990210 <--
                                             CA 2000-2362715     A3 20000208 <--
                                             EP 2000-902730      A3 20000208 <--
                                             EP 2005-4285        A3 20000208 <--
                                             JP 2000-598164      A3 20000208 <--
                                             WO 2000-GB373       W  20000208 <--
                                             KR 2001-710133      A3 20010810 <--
                                             US 2002-913020      A3 20020506 <--
OTHER SOURCE(S):         MARPAT 133:177183
GI
```



I



II

AB The title compds. (I) [wherein A = an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic ring optionally containing 1-3 O, N, and/or S heteroatoms; Z = O, NH, S, CH2, or a bond; n = 0-5; m = 0-3; R2 = H, OH, halo, CN, NO2, CF3, alkyl(sulfanyl), alkoxy, NR3N4, or R5X1; R3 and R4 = independently H or alkyl; X1 = a bond, O, CH2, OC(O), CO, S, SO, SO2, NR6CO, CONR7, SO2R8, NR9SO2, or NR10; R5 = H or (un)substituted alkyl, alkenyl, alkynyl, or heterocyclyl, etc.; R6-R10 = independently H or (alkoxy)alkyl] were prepared for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. For instance, II was synthesized in a 9-step sequence starting with the cyclization of 2-amino-4-benzyloxy-5-methoxybenzamide using Gold's reagent in dioxane to form 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (84%). I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis (no data).

IT 288383-64-2P, 7-Benzyloxy-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-65-3P, 7-Hydroxy-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288384-15-6P, 7-[2-(1-(tert-Butoxycarbonyl)piperidin-4-yl)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288384-17-8P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yl)ethoxy]quinazoline 288386-84-5P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288383-64-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)- (CA INDEX NAME)



RN 288383-65-3 CAPLUS
CN 7-Quinazolinol, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288384-15-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288384-17-8 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288386-84-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 288382-20-7P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288382-22-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-24-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-26-3P, 6-Methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-30-9P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288382-32-1P, 7-(3-(N,N-Dimethylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-34-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288382-36-5P, 7-[2-(N,N-Diethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-38-7P, 4-(2-Methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-39-8P, 4-(2-Methylindol-5-yloxy)-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-40-1P, 4-(2-Methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-41-2P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline 288382-42-3P, 7-[3-(Methylsulfonyl)propoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-43-4P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288382-44-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)quinazoline 288382-45-6P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-46-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288382-47-8P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-48-9P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-49-0P, 7-[3-(Ethylsulfonyl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-50-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-51-4P, 7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-52-5P, 7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-53-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methylamino)ethoxy]quinazoline 288382-54-7P, 7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-56-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-57-0P, 4-(Indol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288382-58-1P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-

ylpropoxy)quinazoline 288382-59-2P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulfonylpropoxy)quinazoline
288382-60-5P, 7-[(1-(Cyanomethyl)piperidin-4-yl)methoxy]-6-methoxy-
4-(2-methylindol-5-yloxy)quinazoline 288382-61-6P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline
288382-62-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-
1-ylethoxy)quinazoline 288382-63-8P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-methylpiperidin-3-
yl)methoxy)quinazoline 288382-64-9P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline
288382-65-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[N-methyl-N-
(4-pyridyl)amino]ethoxy]quinazoline 288382-66-1P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline
288382-67-2P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(2-
methylindol-5-yloxy)quinazoline 288382-68-3P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-
yl)ethoxy]quinazoline 288382-69-4P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[2-(4-methylpiperazin-1-
yl)ethoxy]ethoxy]quinazoline 288382-70-7P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline
288382-71-8P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-
piperidinopropoxy)quinazoline 288382-72-9P
288382-73-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(4-
methylpiperazin-1-yl)propoxy]quinazoline 288382-74-1P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline
288382-75-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-
4-yloxy)ethoxy]quinazoline 288382-76-3P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methyl-N-
methylsulfonylamino)ethoxy]quinazoline 288382-77-4P,
7-[2-[[1-(2-Cyanoethyl)piperidin-4-yl]oxy]ethoxy]-6-methoxy-4-(2-
methylindol-5-yloxy)quinazoline 288382-78-5P,
4-(2-Methylindol-5-yloxy)-7-[3-(pyrrolidinyl)propoxy]quinazoline
288382-79-6P, 4-(2-Methylindol-5-yloxy)-7-[3-(1,1-
dioxothiomorpholino)propoxy]quinazoline 288382-80-9P,
4-(2-Methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline
288382-81-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-
methoxyethoxy)ethoxy]quinazoline 288382-82-1P,
7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline
288382-83-2P, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-
methoxyquinazoline 288382-84-3P,
7-[3-(1,1-Dioxothiomorpholino)propoxy]-4-(indol-5-yloxy)-6-
methoxyquinazoline 288382-85-4P,
4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline
288382-86-5P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-
piperidinopropoxy)quinazoline 288382-87-6P,
7-[[1-(2-Methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-
yloxy)quinazoline 288382-88-7P,
7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288382-89-8P,
7-[2-[1-(2-Methoxyethyl)piperidin-4-yl]ethoxy]-6-methoxy-4-(2-methylindol-
5-yloxy)quinazoline 288382-90-1P,
7-(2-Hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288382-91-2P,
7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288382-92-3P,
7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288382-93-4P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(4-pyridyloxy)ethoxy]quinazoline
288382-94-5P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-
morpholinopropoxy)quinazoline 288382-95-6P,
(R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-
piperidinopropoxy)quinazoline 288382-96-7P,

(R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288382-97-8P, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-98-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-[2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl]methoxy]quinazoline 288382-99-0P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-06-2P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-07-3P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-08-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-morpholinoethyl)piperidin-4-yl]methoxy]quinazoline 288383-11-9P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)quinazoline 288383-12-0P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288383-13-1P, 4-(6-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-14-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-22-2P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288383-26-6P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-37-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-methylsulfonylethyl)piperidin-4-yl]methoxy]quinazoline 288383-66-4P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288383-68-6P, 7-[2-(N,N-Dimethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-70-0P,

6-Methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-75-5P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline 288383-76-6P, 6-Methoxy-7-[[1-(2-methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-81-3P, 7-(3-Chloropropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-82-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy]ethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-88-0P, 4-(2-Methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288383-89-1P, 4-(2-Methylindol-5-yloxy)-7-[3-(piperidin-1-yl)propoxy]quinazoline 288383-90-4P, 7-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)-4-(2-methylindol-5-yloxy)quinazoline 288383-92-6P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288383-94-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288383-95-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288383-96-0P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-97-1P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-98-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline 288383-99-3P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-oxopyrrolidin-1-yl)ethoxy]quinazoline 288384-00-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288384-01-0P, 4-(2,3-Dimethylindol-5-yloxy)-7-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-6-methoxyquinazoline 288384-02-1P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-03-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-04-3P, 4-(2,3-Dimethylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]-6-methoxyquinazoline 288384-05-4P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288384-06-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-08-7P, 7-Benzyloxy-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-09-8P , 7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-10-1P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline 288384-11-2P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-12-3P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-14-5P, 4-(2,3-Dimethylindol-5-yloxy)-7-(3-ethylsulfonylpropoxy)-6-methoxyquinazoline 288384-16-7P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-(3-morpholinopropoxy)quinazoline 288384-39-4P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-40-7P, 4-(1,2-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-42-9P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-49-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-59-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-63-4P, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline

288384-64-5P, 4-(Indol-4-yloxy)-6-methoxy-7-(3-
piperidinopropoxy)quinazoline 288384-69-0P,
7-Benzyloxy-4-((1-tert-butoxycarbonyl-2,3-dimethylindol-5-yl)oxy)-6-
methoxyquinazoline 288384-75-8P,
6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-
yl)propoxy]quinazoline 288384-76-9P,
6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline
288384-78-1P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-
methylsulfonylamino)propoxy]quinazoline 288384-82-7P,
4-(2-Carboxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline
288385-18-2P, 4-(2,3-Dihydro-1H-indol-5-yl)oxy-6-methoxy-7-[3-
(pyrrolidin-1-yl)propoxy]quinazoline 288385-86-4P,
7-[[1-(Cyanomethyl)piperidin-4-yl]methoxy]-4-(indol-5-yloxy)-6-
methoxyquinazoline 288386-17-4P,
4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-
yl)methoxy)quinazoline 288386-24-3P,
4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-
yl)propoxy]quinazoline 288386-27-6P,
4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline
288386-31-2P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-(3-
morpholinopropoxy)quinazoline 288386-32-3P,
4-(Indol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline
288386-33-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-
yl)ethoxy]quinazoline 288386-34-5P,
4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-methylpiperazin-1-
yl)ethoxy]quinazoline 288386-36-7P,
4-(Indol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-
yl)propoxy]quinazoline 288386-68-5P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-methyl-2-oxopiperidin-4-
yl)methoxy)quinazoline 288386-73-2P,
(R)-7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288386-77-6P,
7-Hydroxy-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline
288386-79-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-
morpholinopropoxy)quinazoline 288386-81-2P,
6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline
288386-88-9P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-
(3-methylindol-5-yloxy)quinazoline 288386-90-3P,
6-Methoxy-4-(3-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline
288386-92-5P, 7-((1-(Cyanomethyl)piperidin-4-yl)methoxy)-6-methoxy-
4-(3-methylindol-5-yloxy)quinazoline 288386-94-7P,
(R)-6-Methoxy-4-(3-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline
288386-97-0P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-
6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288386-99-2P,
(R)-7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(3-methylindol-5-
yloxy)quinazoline 288387-01-9P,
(R)-7-(2-Hydroxy-3-dimethylaminopropoxy)-6-methoxy-4-(3-methylindol-5-
yloxy)quinazoline 288387-03-1P,
(R)-7-[2-Hydroxy-3-(N,N-diethylamino)propoxy]-6-methoxy-4-(3-methylindol-5-
yloxy)quinazoline 288387-05-3P,
(R)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-
yloxy)quinazoline 288387-07-5P,
(R)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-6-methoxy-4-(3-
methylindol-5-yloxy)quinazoline 288387-09-7P,
(R)-7-[2-Hydroxy-3-(3-morpholinopropylamino)propoxy]-6-methoxy-4-(3-
methylindol-5-yloxy)quinazoline 288387-11-1P,
(R)-7-[2-Hydroxy-3-[(3-(4-methylpiperazin-1-yl)propyl)amino]propoxy]-6-
methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-13-3P,
(R)-7-[2-Hydroxy-3-[[3-(pyrrolidin-1-yl)propyl]amino]propoxy]-6-methoxy-4-
(3-methylindol-5-yloxy)quinazoline 288387-19-9P,
6-Methoxy-4-(1-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline
288387-23-5P, (R)-7-(2-Hydroxy-3-dimethylaminopropoxy)-4-(indol-5-

yloxy)-6-methoxyquinazoline 288387-25-7P,
(R)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-29-1P,
(S)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-31-5P,
(S)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-33-7P,
(S)-7-(2-Hydroxy-3-dimethylaminopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-35-9P,
(R)-7-(2-Hydroxy-3-(isopropylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-37-1P,
(S)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-41-7P,
(S)-7-(2-Hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288387-42-8P,
(S)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288387-43-9P,
(R)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288387-44-0P,
6-Methoxy-4-(1-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288387-45-1P, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(2-piperidinopropoxy)quinazoline 288387-46-2P,
6-Methoxy-4-(1-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288387-47-3P,
6-Methoxy-4-(4-nitroindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288387-50-8P, 4-(4-Aminoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288387-51-9P,
6-Methoxy-7-(3-piperidinopropoxy)-4-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)quinazoline 288387-53-1P,
4-(Indol-5-yloxy)-6-methoxy-7-[3-(4-piperidinylpiperidino)propoxy]quinazoline 288387-55-3P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-((1-methyl-2-oxopyrrolidin-5-yl)methoxy)quinazoline 288387-57-5P,
(S)-4-(1H-Indol-5-yloxy)-6-methoxy-7-((2-oxopyrrolidin-5-yl)methoxy)quinazoline 288387-59-7P,
(R)-4-(1H-Indol-5-yloxy)-6-methoxy-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288387-60-0P,
6-Methoxy-4-[1-(3-piperidinopropyl)-1H-indol-5-yloxy]-7-(3-piperidinopropoxy)quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288382-20-7 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288382-22-9 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288382-24-1 CAPLUS
CN Quinazoline, 6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-[[2-(trifluoromethyl)-1H-indol-5-yl]oxy]- (CA INDEX NAME)



RN 288382-26-3 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-[[2-(trifluoromethyl)-1H-indol-5-yl]oxy]- (CA INDEX NAME)



RN 288382-30-9 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (CA INDEX NAME)



RN 288382-32-1 CAPLUS
CN 1-Propanamine, 3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 288382-34-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-[2-(4-morpholinyl)ethoxy]ethoxy]- (CA INDEX NAME)



RN 288382-36-5 CAPLUS
CN Ethanamine, N,N-diethyl-2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]- (CA INDEX NAME)



RN 288382-38-7 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]-
(CA INDEX NAME)



RN 288382-39-8 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]-
(CA INDEX NAME)



RN 288382-40-1 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1H-1,2,4-triazol-1-
yl)ethoxy]- (CA INDEX NAME)



RN 288382-41-2 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-[[6-
(trifluoromethyl)-1H-indol-5-yl]oxy]- (CA INDEX NAME)



RN 288382-42-3 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(methylsulfonyl)propoxy]- (CA INDEX NAME)



RN 288382-43-4 CAPLUS
CN 1-Propanamine, 3-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 288382-44-5 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288382-45-6 CAPLUS
CN Ethanamine, N,N-diethyl-2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]- (CA INDEX NAME)



RN 288382-46-7 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(2-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288382-47-8 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288382-48-9 CAPLUS
CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288382-49-0 CAPLUS
CN Quinazoline, 7-[3-(ethylsulfonyl)propoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288382-50-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288382-51-4 CAPLUS
CN 1-Piperidineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 288382-52-5 CAPLUS
CN 1-Piperazineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-4-methyl- (CA INDEX NAME)



RN 288382-53-6 CAPLUS
CN Ethanamine, 2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N-methyl- (CA INDEX NAME)



RN 288382-54-7 CAPLUS
CN 2-Propanol, 1-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]- (CA INDEX NAME)



RN 288382-56-9 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288382-57-0 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288382-58-1 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288382-59-2 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(methylsulfonyl)propoxy]- (CA INDEX NAME)



RN 288382-60-5 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 288382-61-6 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 288382-62-7 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 288382-63-8 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(1-methyl-3-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288382-64-9 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288382-65-0 CAPLUS
CN 4-Pyridinamine, N-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 288382-66-1 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288382-67-2 CAPLUS
CN Quinazoline, 6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288382-68-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (CA INDEX NAME)



RN 288382-69-4 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-[2-(4-methyl-1-piperazinyl)ethoxy]ethoxy]- (CA INDEX NAME)



RN 288382-70-7 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288382-71-8 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288382-72-9 CAPLUS
CN 2-Propenamide, 3-[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 288382-73-0 CAPLUS

CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288382-74-1 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 288382-75-2 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-piperidinyloxy)ethoxy]- (CA INDEX NAME)



RN 288382-76-3 CAPLUS
CN Methanesulfonamide, N-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 288382-77-4 CAPLUS
CN 1-Piperidinepropanenitrile, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethoxy]- (CA INDEX NAME)



RN 288382-78-5 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288382-79-6 CAPLUS
CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288382-80-9 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)-
(CA INDEX NAME)



RN 288382-81-0 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-
(CA INDEX NAME)



RN 288382-82-1 CAPLUS
CN 1-Propanamine, 3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-N,N-
dimethyl- (CA INDEX NAME)



RN 288382-83-2 CAPLUS
CN 1-Propanamine, N,N-diethyl-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-

quinazolinyl]oxy]- (CA INDEX NAME)



RN 288382-84-3 CAPLUS
CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-(1H-indol-5-yloxy)-6-methoxy- (CA INDEX NAME)



RN 288382-85-4 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy]- (CA INDEX NAME)



RN 288382-86-5 CAPLUS
CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288382-87-6 CAPLUS
CN Quinazoline, 7-[[1-(2-methoxyethyl)-4-piperidinyl]methoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288382-88-7 CAPLUS
CN 4-Morpholineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 288382-89-8 CAPLUS
CN Quinazoline, 6-methoxy-7-[2-[1-(2-methoxyethyl)-4-piperidinyl]ethoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288382-90-1 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 288382-91-2 CAPLUS
CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]- (CA INDEX NAME)



RN 288382-92-3 CAPLUS
CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288382-93-4 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-pyridinyloxy)ethoxy]- (CA INDEX NAME)



RN 288382-94-5 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]-
(CA INDEX NAME)



RN 288382-95-6 CAPLUS
CN 1-Piperidineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-
7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288382-96-7 CAPLUS
CN 2-Pyrrolidinone, 5-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-
quinazolinyl]oxy]methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288382-97-8 CAPLUS
CN Quinazoline, 4-[(4-bromo-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-

piperidinyl)propoxy]- (CA INDEX NAME)



RN 288382-98-9 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[2-(1-pyrrolidinyl)ethyl]-4-piperidinyl]methoxy]- (CA INDEX NAME)



RN 288382-99-0 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-00-6 CAPLUS
CN 4-Morpholineethanol, α-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-01-7 CAPLUS
CN 1-Piperidineethanol, α-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-02-8 CAPLUS
CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-03-9 CAPLUS
CN 1-Piperidineethanol, α-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-04-0 CAPLUS
CN 1-Piperidineethanol, α-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-05-1 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-06-2 CAPLUS

CN 1-Pyrrolidineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-07-3 CAPLUS
CN 1-Piperazineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-4-methyl-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-08-4 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]methoxy]- (CA INDEX NAME)



RN 288383-11-9 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-(1H-pyrrolo[2,3-

b]pyridin-6-yloxy)- (CA INDEX NAME)



RN 288383-12-0 CAPLUS
CN 1-Piperidineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-13-1 CAPLUS
CN Quinazoline, 4-[(6-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-14-2 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-15-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288383-16-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288383-17-5 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-18-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-

pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-19-7 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-21-1 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288383-22-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288383-23-3 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288383-24-4 CAPLUS
CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288383-25-5 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288383-26-6 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288383-37-9 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]- (CA INDEX NAME)



RN 288383-66-4 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(methylsulfonyl)propoxy]-4-[[2-(trifluoromethyl)-1H-indol-5-yl]oxy]- (CA INDEX NAME)



RN 288383-68-6 CAPLUS
CN Ethanamine, 2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 288383-70-0 CAPLUS
CN Ethanamine, N-(2-methoxyethyl)-2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-N-methyl- (CA INDEX NAME)



RN 288383-75-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288383-76-6 CAPLUS
CN Quinazoline, 6-methoxy-7-[[1-(2-methoxyethyl)-4-piperidinyl]methoxy]-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288383-81-3 CAPLUS
CN Quinazoline, 7-(3-chloropropoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288383-82-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288383-84-6 CAPLUS

CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-
(CA INDEX NAME)



RN 288383-88-0 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]-
(CA INDEX NAME)



RN 288383-89-1 CAPLUS
CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]-
(CA INDEX NAME)



RN 288383-90-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2-methyl-1H-indol-5-yl)oxy]-7-
quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288383-92-6 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 288383-94-8 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (CA INDEX NAME)



RN 288383-95-9 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]- (CA INDEX NAME)



RN 288383-96-0 CAPLUS
CN Ethanamine, 2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-N,N-diethyl- (CA INDEX NAME)



RN 288383-97-1 CAPLUS
CN Ethanamine, 2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 288383-98-2 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 288383-99-3 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 288384-00-9 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(2-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288384-01-0 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 288384-02-1 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288384-03-2 CAPLUS
CN Ethanamine, N-[2-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 288384-04-3 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy- (CA INDEX NAME)



RN 288384-05-4 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy]- (CA INDEX NAME)



RN 288384-06-5 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (CA INDEX NAME)



RN 288384-08-7 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-(phenylmethoxy)- (CA INDEX NAME)



RN 288384-09-8 CAPLUS
CN Ethanamine, 2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 288384-10-1 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-1-methyl-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 288384-11-2 CAPLUS
CN Ethanamine, N-[2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 288384-12-3 CAPLUS
CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy]- (CA INDEX NAME)



RN 288384-14-5 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-7-[3-(ethylsulfonyl)propoxy]-6-methoxy- (CA INDEX NAME)



RN 288384-16-7 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288384-39-4 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-6-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288384-40-7 CAPLUS
CN Quinazoline, 4-[(1,2-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288384-42-9 CAPLUS
CN Methanesulfonamide, N-[3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)



RN 288384-49-6 CAPLUS
CN Methanesulfonamide, N-[3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)



RN 288384-59-8 CAPLUS
CN Methanesulfonamide, N-[3-[[4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)



RN 288384-63-4 CAPLUS
CN Quinazoline, 6-methoxy-4-[(6-methoxy-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288384-64-5 CAPLUS
CN Quinazoline, 4-(1H-indol-4-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288384-69-0 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2,3-dimethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288384-75-8 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288384-76-9 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 288384-78-1 CAPLUS
CN Methanesulfonamide, N-[3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)



RN 288384-82-7 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]- (CA INDEX NAME)



RN 288385-18-2 CAPLUS
CN Quinazoline, 4-[(2,3-dihydro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288385-86-4 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 288386-17-4 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 288386-24-3 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288386-27-6 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-

piperidinyl)propoxy]- (CA INDEX NAME)



RN 288386-31-2 CAPLUS
CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288386-32-3 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 288386-33-4 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 288386-34-5 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 288386-36-7 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 288386-68-5 CAPLUS
CN 2-Piperidinone, 4-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-1-methyl- (CA INDEX NAME)



RN 288386-73-2 CAPLUS
CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288386-77-6 CAPLUS
CN 7-Quinazolinol, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288386-79-8 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288386-81-2 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 288386-88-9 CAPLUS
CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288386-90-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 288386-92-5 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 288386-94-7 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[(2R)-2-

oxiranylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 288386-97-0 CAPLUS
CN 1-Piperazineethanol, α-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-
    7-quinazolinyl]oxy]methyl]-4-methyl-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288386-99-2 CAPLUS
CN 4-Morpholineethanol, α-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-
    7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-01-9 CAPLUS
CN 2-Propanol, 1-(dimethylamino)-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-03-1 CAPLUS
CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-05-3 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-07-5 CAPLUS
CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-09-7 CAPLUS
CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(4-morpholinyl)propyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-11-1 CAPLUS
CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(4-methyl-1-piperazinyl)propyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-13-3 CAPLUS
CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(1-pyrrolidinyl)propyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-19-9 CAPLUS
CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288387-23-5 CAPLUS
CN 2-Propanol, 1-(dimethylamino)-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-25-7 CAPLUS
CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-29-1 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-31-5 CAPLUS
CN 4-Morpholineethanol, α-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-33-7 CAPLUS
CN 2-Propanol, 1-(dimethylamino)-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-35-9 CAPLUS
CN 2-Propanol, 1-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-37-1 CAPLUS
CN 2-Propanol, 1-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-41-7 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-42-8 CAPLUS
CN 2-Propanol, 1-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-43-9 CAPLUS
CN 2-Propanol, 1-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-44-0 CAPLUS
CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 288387-45-1 CAPLUS
CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288387-46-2 CAPLUS
CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288387-47-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(4-nitro-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)



RN 288387-50-8 CAPLUS
CN 1H-Indol-4-amine, 5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]- (CA INDEX NAME)



RN 288387-51-9 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (CA INDEX NAME)



RN 288387-53-1 CAPLUS
CN Quinazoline, 7-(3-[1,4'-bipiperidin]-1'-ylpropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (CA INDEX NAME)



RN 288387-55-3 CAPLUS
CN 2-Pyrrolidinone, 5-[[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-

quinazolinyl]oxy]methyl]-1-methyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-57-5 CAPLUS
CN 2-Pyrrolidinone, 5-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-59-7 CAPLUS
CN 2-Pyrrolidinone, 5-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-60-0 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-[[1-[3-(1-piperidinyl)propyl]-1H-indol-5-yl]oxy]- (CA INDEX NAME)



IT 288384-07-6P, 7-Hydroxy-4-(indol-5-yloxy)-6-methoxyquinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)
RN 288384-07-6 CAPLUS
CN 7-Quinazolinol, 4-(1H-indol-5-yloxy)-6-methoxy- (CA INDEX NAME)



IT 288383-77-7P, 7-(2-Carboxyvinyl)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-85-7P, 7-Hydroxy-4-(2-methylindol-5-yloxy)quinazoline 288383-87-9P, 7-Benzyloxy-4-(2-methylindol-5-yloxy)quinazoline 288383-91-5P, 4-(2,3-Dimethylindol-5-yloxy)-7-hydroxy-6-methoxyquinazoline 288383-93-7P, 7-Benzyloxy-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288384-60-1P, 7-(2,3-Epoxypropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288385-15-9P, 4-((1-tert-Butoxycarbonyl-2,3-dihydroindol-5-yl)oxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-24-0P, 4-((1-tert-Butoxycarbonyl-2,3-dihydroindol-5-yl)oxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288386-37-8P, (R)-7-[2-Acetoxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288386-71-0P, (R)-6-Methoxy-4-(2-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline 288386-75-4P, 7-Benzyloxy-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-21-3P, (R)-4-(Indol-5-yloxy)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazoline 288387-27-9P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazoline 288387-39-3P, (S)-6-Methoxy-4-(2-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline 288387-52-0P, 7-(3-Bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxyquinazoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines as angiogenesis inhibitors by

cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288383-77-7 CAPLUS

CN 2-Propenoic acid, 3-[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]- (CA INDEX NAME)



RN 288383-85-7 CAPLUS

CN 7-Quinazolinol, 4-[(2-methyl-1H-indol-5-yl)oxy]- (CA INDEX NAME)



RN 288383-87-9 CAPLUS

CN Quinazoline, 4-[(2-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)- (CA INDEX NAME)



RN 288383-91-5 CAPLUS

CN 7-Quinazolinol, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy- (CA INDEX NAME)



RN 288383-93-7 CAPLUS
CN Quinazoline, 4-[(2,3-dimethyl-1H-indol-5-yl)oxy]-6-methoxy-7-(phenylmethoxy)- (CA INDEX NAME)



RN 288384-60-1 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-(2-oxiranylmethoxy)- (CA INDEX NAME)



RN 288385-15-9 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288385-24-0 CAPLUS
CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[[6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 288386-37-8 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1-acetate, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 288386-71-0 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(2R)-2-

oxiranylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 288386-75-4 CAPLUS
CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)-
(CA INDEX NAME)



RN 288387-21-3 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2R)-2-oxiranylmethoxy]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 288387-27-9 CAPLUS
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-2-oxiranylmethoxy]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 288387-39-3 CAPLUS
CN Quinazoline, 6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-[(2S)-2-oxiranylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-52-0 CAPLUS
CN Quinazoline, 7-(3-bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (CA INDEX NAME)



IT 288383-83-5, 6-Methoxy-4-((2-methylindol-5-yl)oxy)-7-[2-(N-methyl-N-tert-butoxycarbonylamino)ethoxy]quinazoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)
RN 288383-83-5 CAPLUS
CN Carbamic acid, [2-[[6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:113672 CAPLUS
DOCUMENT NUMBER: 130:182476
TITLE: Preparation of heterocyclic compounds as irreversible bicyclic inhibitors of tyrosine kinases
INVENTOR(S): Bridges, Alexander James
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9906396	A1	19990211	WO 1998-US15592		19980729	<--
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
AU 9886659	A	19990222	AU 1998-86659		19980729	<--
US 6153617	A	20001128	US 1999-269647		19990325	<--
US 20030087881	A1	20030508	US 2002-272651		20021017	<--
PRIORITY APPLN. INFO.:			US 1997-54061P	P	19970729	<--
			WO 1998-US15592	W	19980729	<--
			US 1999-269647	A3	19990325	<--
			US 2000-656331	B1	20000906	<--

OTHER SOURCE(S): MARPAT 130:182476
GI



AB The title compds., e.g. I [X = DEF, Y = SR4, etc. ; or X = SR4, etc., and Y = DEF; D = O, etc.; E = CO, etc.; F = CR1(:C):C(R5)H, etc.; a proviso is given; R1 = H, halo, etc.; R5 = H, halo, perfluoroalkyl, etc.; Z = indoline moiety (generic structure given), etc.; R4 = H, alkyl, etc.], are prepared This invention also provides a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases. N-[4-(6-bromo-2,3-dihydroindol-1-yl)quinazolin-6-yl]acrylamide in vitro showed IC50 of 0.4 nM against epidermal growth factor receptor tyrosine kinase.

IT 220575-98-4P 220575-99-5P 220576-02-3P
220576-04-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as irreversible bicyclic inhibitors of tyrosine kinases)

RN 220575-98-4 CAPLUS

CN 2-Octenamide, N-[4-[2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]-6-quinazolinyl]-4,4-difluoro-8-(4-morpholinyl)- (CA INDEX NAME)



RN 220575-99-5 CAPLUS

CN 2-Pentenediamide, N1-[4-[2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]-6-quinazolinyl]-N5-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 220576-02-3 CAPLUS

CN 2-Butenamide, N-[4-(2,3-dihydro-5-methoxy-1H-indol-1-yl)-6-quinazolinyl]-4-[[3-(4-morpholinyl)propyl]thio]- (CA INDEX NAME)



RN 220576-04-5 CAPLUS
CN 2-Heptynamide, N-[4-(2,3-dihydro-5-methoxy-1H-indol-1-yl)-6-quinazolinyl]-7-(4-morpholinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:219346 CAPLUS
DOCUMENT NUMBER: 128:270611
ORIGINAL REFERENCE NO.: 128:53569a,53572a
TITLE: Preparation of 4-heterocyclylquinazolines as anticancer agents.
INVENTOR(S): Arnold, Lee D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 30 pp., Cont.-in-part of U.S. Ser. No. 200,259, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736534	A	19980407	US 1996-682565	19960729 <--
WO 9523141	A1	19950831	WO 1995-IB61	19950127 <--
W: AU, BR, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1994-200259 B2 19940223 <--
WO 1995-IB61 W 19950127 <--
OTHER SOURCE(S): MARPAT 128:270611
GI



I

AB Title compds. [I; Z = specified (substituted) N-heterocyclyl; R1 = CF3, halo, NO2, OH, amino, cyano, alkyl, alkoxy, alkoxycarbonyl, alkanoyloxy, alkanoylamino, CO2H, PhO, PhCO2, carbamoyl, hydroxyalkyl, alkylthio, anilino, pyrrolidinyl, etc.; m = 0-3], were prepared as neoplasm inhibitors (no data). Thus, 6-chloroindoline, 4-chloro-6,7-ethylenedioxyquinazoline, and pyridine were refluxed in iPrOH to give 4-(6-chloro-2,3-dihydroindol-1-yl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazoline.

IT 172078-61-4P 172078-86-3P 172078-87-4P
172078-92-1P 172078-93-2P 172078-94-3P
172079-02-6P 205584-51-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-heterocyclylquinazolines as anticancer agents)

RN 172078-61-4 CAPLUS

CN Quinazoline, 4-(2,3-dihydro-6-methoxy-1H-indol-1-yl)-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 172078-86-3 CAPLUS

CN Quinazoline, 4-(2,3-dihydro-5-methoxy-1H-indol-1-yl)-6,7-dimethoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172078-85-2
CMF C19 H19 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 172078-87-4 CAPLUS
CN Quinazoline, 4-[2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]-6,7-dimethoxy- (CA INDEX NAME)



RN 172078-92-1 CAPLUS
CN 1H-Indol-5-ol, 1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172078-91-0
CMF C18 H17 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 172078-93-2 CAPLUS
CN 1H-Indol-5-ol, 1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-6-methyl- (CA INDEX NAME)



RN 172078-94-3 CAPLUS
CN 1H-Indol-5-ol, 1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-6-methyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172078-93-2
CMF C19 H19 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 172079-02-6 CAPLUS
CN 1H-Indol-5-ol, 6-chloro-1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172079-01-5
CMF C18 H16 Cl N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 205584-51-6 CAPLUS
CN Quinazoline, 4-[2,3-dihydro-6-(phenylmethoxy)-1H-indol-1-yl]-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:756964 CAPLUS
DOCUMENT NUMBER: 128:22920
ORIGINAL REFERENCE NO.: 128:4495a,4498a
TITLE: Oxindolylquinazoline derivatives as angiogenesis inhibitors
INVENTOR(S): Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Lohmann, Jean-jacques Marcel; Ple, Patrick
PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Lohmann, Jean-Jacques Marcel; Ple, Patrick
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9742187	A1	19971113	WO 1997-GB1211		19970502	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU						
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG						
AU 9726475	A	19971126	AU 1997-26475		19970502	<--
EP 912557	A1	19990506	EP 1997-918293		19970502	<--
EP 912557	B1	20030709				
R: CH, DE, FR, GB, IT, LI						
JP 2000510115	T	20000808	JP 1997-539644		19970502	<--
JP 4201836	B2	20081224				
ZA 9703844	A	19971106	ZA 1997-3844		19970505	<--
IN 1997DE01160	A	20050311	IN 1997-DE1160		19970505	<--
US 6265411	B1	20010724	US 1998-180310		19981106	<--
PRIORITY APPLN. INFO.:			EP 1996-400956	A	19960506	<--
			EP 1996-400957	A	19960506	<--
			EP 1996-402762	A	19961217	<--
			EP 1996-402763	A	19961217	<--
			WO 1997-GB1211	W	19970502	<--

OTHER SOURCE(S): MARPAT 128:22920
GI



I

AB Title compds. I [R = H, alkyl, alkoxymethyl, dialkoxymethyl, alkanoyl and the benzene rings may be further substituted] were prepared for use in inhibiting angiogenesis and reducing vascular permeability (no data). Thus, 4,5-dimethoxyanthranilic acid was converted to 6,7-dimethoxyquinazoline by treatment with HCONH2 and was treated with 1-methyloxindole to give 6,7-dimethoxy-4-(1-methyl-3-oxindolyl)quinazoline.

IT 199327-49-6P 199327-85-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxindolylquinazoline derivs. as angiogenesis and vascular permeability inhibitors)

RN 199327-49-6 CAPLUS
CN 2H-Indol-2-one, 1-(diethoxymethyl)-1,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-5-(phenylmethoxy)- (CA INDEX NAME)



RN 199327-85-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-5-(methylthio)-, hydrochloride (2:3) (CA INDEX NAME)



●3/2 HCl

IT 199327-50-9P 199327-62-3P 199327-87-2P
199327-89-4P 199328-03-5P 199328-09-1P
199328-13-7P 199328-23-9P 199328-28-4P
199328-30-8P 199328-53-5P 199328-58-0P
199328-60-4P 199328-73-9P 199328-79-5P
199328-81-9P 199328-83-1P 199328-85-3P
199328-90-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxindolylquinazoline derivs. as angiogenesis and vascular permeability inhibitors)

RN 199327-50-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-, hydrochloride (2:3) (CA INDEX NAME)



●3/2 HCl

RN 199327-62-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5,6-dimethoxy-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 199327-87-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[6-methoxy-7-[3-(4-oxido-4-morpholinyl)propoxy]-4-quinazolinyl]-5-(methylsulfinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 199327-89-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-5-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 199328-03-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-5-(methylsulfonyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 199328-09-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-5-(methylsulfinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 199328-13-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-N-[2-(4-morpholinyl)ethyl]-2-oxo-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 199328-23-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-N-[2-(4-morpholinyl)ethyl]-2-oxo-, hydrochloride (2:3) (CA INDEX NAME)



● 3/2 HCl

RN 199328-28-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]-N-[2-(4-morpholinyl)ethyl]-2-oxo-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 199328-30-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 199328-53-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-2-oxo-, hydrochloride (2:3) (CA INDEX NAME)



●3/2 HCl

RN 199328-58-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-N-methyl-2-oxo-, hydrochloride (2:3) (CA INDEX NAME)



●3/2 HCl

RN 199328-60-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-N-methyl-2-oxo-, hydrochloride (2:1) (CA INDEX NAME)



●1/2 HCl

RN 199328-73-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-N,N-dimethyl-2-oxo-, hydrochloride (4:3) (CA INDEX NAME)



●3/4 HCl

RN 199328-79-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-quinazolinyl]-2-oxo-, hydrochloride (2:1) (CA INDEX NAME)



●1/2 HCl

RN 199328-81-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-N,N-dimethyl-2-oxo-, hydrochloride (2:3) (CA INDEX NAME)



●3/2 HCl

RN 199328-83-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]- (CA INDEX NAME)



RN 199328-85-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]-2-oxo- (CA INDEX NAME)



RN 199328-90-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-quinazolinyl]-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:994349 CAPLUS
DOCUMENT NUMBER: 124:55971
ORIGINAL REFERENCE NO.: 124:10581a
TITLE: Preparation of 4-(heterocyclyl)quinazoline-derivative anticancer agents
INVENTOR(S): Arnold, Lee D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9523141	A1	19950831	WO 1995-IB61	19950127 <--
W: AU, BR, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2183655	A1	19950831	CA 1995-2183655	19950127 <--
CA 2183655	C	20010306		
AU 9529727	A	19950911	AU 1995-29727	19950127 <--
AU 686843	B2	19980212		
EP 746554	A1	19961211	EP 1995-905737	19950127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1141633	A	19970129	CN 1995-191723	19950127 <--
JP 09501953	T	19970225	JP 1995-522227	19950127 <--
JP 2890267	B2	19990510		
HU 76291	A2	19970728	HU 1996-2305	19950127 <--
BR 9506936	A	19970909	BR 1995-6936	19950127 <--
RU 2137762	C1	19990920	RU 1996-119255	19950127 <--
CZ 288955	B6	20011017	CZ 1996-2413	19950127 <--
TW 404946	B	20000911	TW 1995-84100928	19950206 <--
ZA 9501458	A	19960822	ZA 1995-1458	19950222 <--
US 5736534	A	19980407	US 1996-682565	19960729 <--
FI 9603283	A	19960822	FI 1996-3283	19960822 <--
NO 9603506	A	19961022	NO 1996-3506	19960822 <--
PRIORITY APPLN. INFO.:			US 1994-200259 A1	19940223 <--
			WO 1995-IB61 W	19950127 <--

OTHER SOURCE(S): MARPAT 124:55971

GI



I

AB The title compds [I; R1 = (un)substituted alkyl, halogen, NO2, OH, NH2, alkoxy, heterocyclo, PhO, etc.; Z = (un)substituted heterocyclo; m = 0-3], useful for the treatment of abnormal proliferation due to cancer (no data), psoriasis (no data), benign prostatic hypertrophy (no data), etc. (no data), are prepared Thus, 6-chloroindoline was reacted with 4-chloro-6,7-(ethylenedioxy)quinazoline and pyridine, producing 4-(6-chloro-2,3-dihydroindol-1-yl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazoline, m.p. 209-211°.

IT 172078-60-3P 172078-61-4P 172078-86-3P
172078-87-4P 172078-92-1P 172078-94-3P
172079-02-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(heterocyclyl)quinazoline-derivative anticancer agents)

RN 172078-60-3 CAPLUS

CN Quinazoline, 4-[2,3-dihydro-6-(phenylmethoxy)-1H-indol-1-yl]-6,7-dimethoxy- (CA INDEX NAME)



RN 172078-61-4 CAPLUS
CN Quinazoline, 4-(2,3-dihydro-6-methoxy-1H-indol-1-yl)-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 172078-86-3 CAPLUS
CN Quinazoline, 4-(2,3-dihydro-5-methoxy-1H-indol-1-yl)-6,7-dimethoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172078-85-2
CMF C19 H19 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 172078-87-4 CAPLUS
CN Quinazoline, 4-[2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]-6,7-dimethoxy-
(CA INDEX NAME)



RN 172078-92-1 CAPLUS
CN 1H-Indol-5-ol, 1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-,
methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172078-91-0
CMF C18 H17 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 172078-94-3 CAPLUS
CN 1H-Indol-5-ol, 1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-6-methyl-,
methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172078-93-2
CMF C19 H19 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 172079-02-6 CAPLUS
CN 1H-Indol-5-ol, 6-chloro-1-(6,7-dimethoxy-4-quinazolinyl)-2,3-dihydro-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 172079-01-5
CMF C18 H16 Cl N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S



OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:435325 CAPLUS
DOCUMENT NUMBER: 121:35325
ORIGINAL REFERENCE NO.: 121:6519a,6522a
TITLE: Bicyclic(azaaromatic)indoles as inhibitors of leukotriene biosynthesis
INVENTOR(S): Frenette, Richard
PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325546	A1	19931223	WO 1993-CA253	19930616 <--
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5334719	A	19940802	US 1992-899399	19920617 <--
AU 9343046	A	19940104	AU 1993-43046	19930616 <--
PRIORITY APPLN. INFO.:			US 1992-899399 A2	19920617 <--
			WO 1993-CA253 A	19930616 <--

OTHER SOURCE(S): MARPAT 121:35325
GI



I



II

AB The title compds. I (Het = heteroaryl; R4, R5 = H, halo, alkyl, etc.; R6 = H, haloalkyl, etc.; R9 = H, substituent; X4 = alkenediyl, etc.; Q = carboxyl, carbamoyl, hydroxyalkyl, etc.) are disclosed as inhibitors of leukotriene biosynthesis. Compds. I are useful as antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea and migraine. A specifically claimed compound is sodium 3-[1-(4-chlorobenzyl)-3-(tert-butylthio)-5-[1-(2-quinolinyl)ethoxy]indol-2-yl]-2,2-dimethylpropanoate (II).

IT 155813-16-4 155813-19-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(leukotriene antagonist)

RN 155813-16-4 CAPLUS

CN 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-α,α-dimethyl-5-[1-(2-quinazolinyl)ethoxy]-, methyl ester (CA INDEX NAME)



RN 155813-19-7 CAPLUS

CN 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)-α,α-dimethyl-5-[1-(2-quinazolinyl)ethoxy]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:560151 CAPLUS
DOCUMENT NUMBER: 85:160151
ORIGINAL REFERENCE NO.: 85:25645a,25648a
TITLE: Indole derivatives
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd., UK
SOURCE: Austrian, 6 pp.
CODEN: AUXXAK
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AT 328433		19760325	AT 1974-1003	19740208 <--
PRIORITY APPLN. INFO.:			GB 1972-18116	19720419 <--

GI



I

AB Quinazolines I [Rn = H, 6,8-Cl2, 7-Cl, 2-MeO, 2-MeS; R1 = Me, R2 = CO2R4 (R4 = Me, Et, Bu, CH2Ph, Ph, CH2CH2NMe2), CONHR5 (R5 = H, Ph), CONR6CONHR6 (R6 = cyclohexyl), CH2OAc; R3 = MeO, NMe2, Me, F; Rn = R1 = R3 = H, R2 = CO2Et] (23 compds.) and the 1-(7-chloro-4-cinnolinyl) and 1-(6-chloro-4-phenyl-2-quinazolinyl) analogs of I (R1 = Me, R2 = CO2Me, R3 = MeO), useful as inflammation inhibitors, analgesics, and antipyretics (no data) were prepared from 4-R3C6H4NHN:CR1CH2CH2R2 and haloquinazolines or a halocinnoline. Thus, 4-MeOC6H4NHN:CMeCH2CH2CO2Et in (MeOCH2)2 was treated with 4-chloroquinazoline in (MeOCH2)2 and the mixture refluxed 4 hr to give I (Rn = H, R1 = Me, R2 = CO2Et, R3 = MeO).

IT 41799-66-0P 41800-03-7P 41800-72-0P
41800-73-1P 41800-74-2P 41800-75-3P
41800-76-4P 41800-77-5P 41800-84-4P
41800-85-5P 41800-86-6P 60638-36-0P
60638-37-1P 60638-38-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41799-66-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



RN 41800-03-7 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



RN 41800-72-0 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)



RN 41800-73-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, butyl ester (CA INDEX NAME)



RN 41800-74-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, ethyl ester (CA INDEX NAME)



RN 41800-75-3 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, phenylmethyl ester (CA INDEX NAME)



RN 41800-76-4 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, phenyl ester (CA INDEX NAME)



RN 41800-77-5 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, cyclohexylmethyl ester (CA INDEX NAME)



RN 41800-84-4 CAPLUS
CN 1H-Indole-3-acetamide, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-N-phenyl- (CA INDEX NAME)



RN 41800-85-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-86-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-(7-chloro-4-quinazolinyl)-N-cyclohexyl-N-[(cyclohexylamino)carbonyl]-5-methoxy-2-methyl- (CA INDEX NAME)



RN 60638-36-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(4-quinazolinyl)-, methyl ester (CA INDEX NAME)



RN 60638-37-1 CAPLUS
CN 1H-Indole-3-ethanol, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, 3-acetate (CA INDEX NAME)



RN 60638-38-2 CAPLUS
CN 1H-Indole-3-carboxylic acid, 1-(7-chloro-4-quinazolinyl)-2-methyl-5-propoxy-, ethyl ester (CA INDEX NAME)



L3 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1975:4289 CAPLUS
DOCUMENT NUMBER: 82:4289
ORIGINAL REFERENCE NO.: 82:743a,746a
TITLE: 1-(4-Quinazolinyl)-3-indoleacetic acids
INVENTOR(S): Doyle, Martin; Smith, Stephen Collyer
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2410699	A1	19740912	DE 1974-2410699	19740306 <--
GB 1407658	A	19750924	GB 1973-10736	19740204 <--
NL 7402369	A	19740910	NL 1974-2369	19740221 <--
DK 134403	B	19761101	DK 1974-1020	19740226 <--
BE 811657	A1	19740827	BE 1974-141465	19740227 <--
DD 110273	A5	19741212	DD 1974-176929	19740304 <--
PL 91000	B1	19770228	PL 1974-169242	19740304 <--
FR 2220528	A1	19741004	FR 1974-7494	19740305 <--
AT 7401823	A	19760415	AT 1974-1823	19740305 <--
AT 333747	B	19761210		
JP 50058083	A	19750520	JP 1974-26098	19740306 <--
CH 612175	A5	19790713	CH 1975-998	19750128 <--
US 4022780	A	19770510	US 1976-679224	19760422 <--
PRIORITY APPLN. INFO.:			GB 1973-10736 A	19730306 <--
			US 1974-441389 A	19740211 <--

GI For diagram(s), see printed CA Issue.

AB Seven acids I (R = H, MeO, or e; R1 = H, Cl-7, Me-2, or SMe-2), useful as analgesics, antipyretics, and inflammation inhibitors (no data) were prepared by reaction of 4-RC6H4NR2N:CMeCH2CH2CO2H (II, R2 = H) with 4-chloroquinazolines, followed by cyclization. Thus, II (R = MeO, R2 = H) reacted with 4,7-dichloroquinazoline in MeOCH2CH2OMe in the presence of HCl in Me2CHOH at room temperature to give II.HCl (R = MeO, R2 = 7-chloro-4-quinazolinyl), which was refluxed in PhMe containing ZnCl2 to give I (R = MeO, R1 = 7-Cl).

IT 41799-92-2P 54367-32-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 41799-92-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 54367-32-7 CAPLUS
CN 1H-Indole-3-propanoic acid, 5-methoxy-2-methyl-1-(2-methyl-4-quinazolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1973:431865 CAPLUS
DOCUMENT NUMBER: 79:31865
ORIGINAL REFERENCE NO.: 79:5169a,5172a
TITLE: Indole derivatives
INVENTOR(S): Birchall, George Richard; Hepworth, Walter; Smith, Stephen Collyer
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: Ger. Offen., 126 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
DE 2253927	A1	19730510	DE 1972-2253927		19721103	<--
GB 1356834	A	19740619	GB 1972-18116		19720419	<--
CA 983932	A1	19760217	CA 1972-152944		19720929	<--
ZA 7207007	A	19730627	ZA 1972-7007		19721002	<--
AU 7247381	A	19740411	AU 1972-47381		19721004	<--
IL 40521	A	19750625	IL 1972-40521		19721006	<--
US 3884919	A	19750520	US 1972-296202		19721010	<--
SU 527135	A3	19760830	SU 1972-1843832		19721020	<--
BE 790679	A1	19730427	BE 1972-123586		19721027	<--
NL 7214807	A	19730507	NL 1972-14807		19721102	<--
FR 2158464	A1	19730615	FR 1972-38836		19721102	<--
JP 48056667	A	19730809	JP 1972-110172		19721102	<--
DD 105611	A5	19740512	DD 1972-166646		19721102	<--
SE 384856	B	19760524	SE 1972-14215		19721102	<--
CH 577499	A5	19760715	CH 1972-15976		19721102	<--
AT 320633	B	19750225	AT 1972-9342		19721103	<--
AT 7401001	A	19750615	AT 1972-100174		19721103	<--
AT 7401002	A	19750615	AT 1972-100274		19721103	<--
AT 7401003	A	19750615	AT 1972-100374		19721103	<--
HU 169711	B	19770228	HU 1972-IE540		19721103	<--
CS 178144	B2	19770831	CS 1972-548		19721103	<--
CS 178120	B2	19770831	CS 1972-7437		19721103	<--
SU 577980	A3	19771025	SU 1974-2043161		19740711	<--
US 4012513	A	19770315	US 1974-535839		19741223	<--
PRIORITY APPLN. INFO.:			GB 1971-51086	A	19711103	<--
			GB 1972-18116	A	19720419	<--
			GB 1972-30767	A	19720630	<--
			US 1972-296202	A2	19721010	<--

GI For diagram(s), see printed CA Issue.

AB Indole derivs. I (e.g. R = CO2H, CH2OH, CONH2; R1 = 4-quinazolyl, 2-benzothiazolyl, pyrimidinyl, 2-quinolyl, quinoxalinyl; R2 = H, MeO) were prepared for use as analgesics, antipyretics, and inflammation inhibitors. Thus I (R = CO2H, R1 = 2-amino-6-methyl-4-pyrimidinyl, R2 = H) was obtained by treating 2-amino-4-chloro-6-methylpyrimidine with PhNHNH2 and cyclizing with levulinic acid.

IT 41801-35-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)

RN 41801-35-8 CAPLUS

CN 1H-Indole-3-acetic acid, 1-(7-amino-4-quinazolinyl)-5-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



IT 41800-00-4 41800-09-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of)

RN 41800-00-4 CAPLUS

CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-2,3-dihydro-5-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



RN 41800-09-3 CAPLUS

CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-2,3-dihydro-5-methoxy-2-methyl-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 41801-00-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)
RN 41801-00-7 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-2-methyl-5-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)



IT 39400-08-3P 41799-10-4P 41799-66-0P
41799-72-8P 41799-83-1P 41799-92-2P
41800-03-7P 41800-54-8P 41800-55-9P
41800-56-0P 41800-58-2P 41800-59-3P
41800-61-7P 41800-71-9P 41800-72-0P
41800-73-1P 41800-74-2P 41800-75-3P
41800-76-4P 41800-77-5P 41800-84-4P
41800-85-5P 41800-86-6P 41800-94-6P
41800-99-1P 41801-01-8P 41801-02-9P
41801-05-2P 41801-15-4P 41801-17-6P
41801-45-0P 41801-46-1P 41801-47-2P
41801-48-3P 41910-16-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39400-08-3 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-4-methoxy-2-methyl-(CA INDEX NAME)



RN 41799-10-4 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-6-methoxy-2-methyl- (CA INDEX NAME)



RN 41799-66-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



RN 41799-72-8 CAPLUS
CN 1H-Indole-3-acetic acid, 2,3-dihydro-5-methoxy-2-methyl-1-(4-quinazolinyl)-, ethyl ester (CA INDEX NAME)



RN 41799-83-1 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(4-quinazolinyl)- (CA INDEX NAME)



RN 41799-92-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-03-7 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, methyl ester (CA INDEX NAME)



RN 41800-54-8 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-α,2-dimethyl-, ethyl ester (CA INDEX NAME)



RN 41800-55-9 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-fluoro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-56-0 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-bromo-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-58-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(7-methyl-4-quinazolinyl)-
(CA INDEX NAME)



RN 41800-59-3 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(2-methyl-4-quinazolinyl)-
(CA INDEX NAME)



RN 41800-61-7 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-α,2-
dimethyl- (CA INDEX NAME)



RN 41800-71-9 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, hydrazide (CA INDEX NAME)



RN 41800-72-0 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)



RN 41800-73-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, butyl ester (CA INDEX NAME)



RN 41800-74-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, ethyl ester (CA INDEX NAME)



RN 41800-75-3 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, phenylmethyl ester (CA INDEX NAME)



RN 41800-76-4 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, phenyl ester (CA INDEX NAME)



RN 41800-77-5 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, cyclohexylmethyl ester (CA INDEX NAME)



RN 41800-84-4 CAPLUS
CN 1H-Indole-3-acetamide, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-N-phenyl- (CA INDEX NAME)



RN 41800-85-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-86-6 CAPLUS
CN 1H-Indole-3-acetamide, 1-(7-chloro-4-quinazolinyl)-N-cyclohexyl-N-[(cyclohexylamino)carbonyl]-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-94-6 CAPLUS
CN 1H-Indole-3-ethanol, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41800-99-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-2-methyl-5-propoxy-, ethyl ester (CA INDEX NAME)



RN 41801-01-8 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-2-methyl-5-(phenylmethoxy)- (CA INDEX NAME)



RN 41801-02-9 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-ethoxy-2-methyl- (CA INDEX NAME)



RN 41801-05-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-2-methyl-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41801-15-4 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-[2-(1-methylethyl)-4-quinazolinyl]- (CA INDEX NAME)



RN 41801-17-6 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(2-ethyl-4-quinazolinyl)-5-methoxy-2-methyl- (CA INDEX NAME)



RN 41801-45-0 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, ammonium salt (1:1) (CA INDEX NAME)



● NH_3

RN 41801-46-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, aluminum salt (3:1) (CA INDEX NAME)



●1/3 Al

RN 41801-47-2 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 41801-48-3 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-2-methyl-, magnesium salt (2:1) (CA INDEX NAME)



●1/2 Mg

RN 41910-16-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-methoxy-α,α,2-trimethyl- (CA INDEX NAME)



IT 41800-98-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with propyl iodide)
RN 41800-98-0 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(7-chloro-4-quinazolinyl)-5-hydroxy-2-methyl-, ethyl ester (CA INDEX NAME)



IT 41801-36-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)

RN 41801-36-9 CAPLUS
CN 1H-Indole-3-acetic acid, 5-methoxy-2-methyl-1-(7-nitro-4-quinazolinyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.82	366.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-25.42	-25.42

STN INTERNATIONAL LOGOFF AT 19:18:46 ON 16 NOV 2009